

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
--------------------	---------------------------------	-------------------------------	----------------------------

LYMPHOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2017)

S1106	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. RW Chen, H Li, SH Bernstein, S Kahwash, LM Rimsza, SJ Forman, L Constine, TC Shea, AF Cashen, KA Blum, TS Fenske, PM Barr, T Phillips, M Leblanc, RI Fisher, BD Cheson, SM Smith, M Faham, J Wilkins, JP Leonard, BS Kahl, JW Friedberg. <i>British Journal of Haematology</i> , Mar;176(5): 759-769, 2017. 2016 Dec 19. doi: 10.1111/bjh.14480. [Epub ahead of print]. PMID27992063; PMC5318240 https://www.ncbi.nlm.nih.gov/pubmed/?term=chen+r+s1106	10/1/11	6/26/13
E2496/COG*	Outcomes in adolescents and young adults (AYA) with hodgkin lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children's Oncology Group (COG AHOD 0031) comparative analysis. TO Henderson, SK Parsons, K Wroblewski, L Chen, F Hong, S Smith, J McNeer, R Advani, R Gascoyne, LS Constine, S Horning, NL Bartlett, B Shah, JM Connors, J Leonard, BS Kahl, K Kelly, CL Schwartz, H Li, JW Friedberg, DL Friedman, LI Gordon, AM Evens. <i>Cancer</i> , in press. 2017. [*COG AHOD 0031]		

LYMPHOMA MANUSCRIPTS SUBMITTED (2017)

S0016	Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. L Rimsza, H Li, R Braziel, C Spier, D Persky, J Dunlap, M LeBlanc, N Barlett, JP Leonard, SM Smith, OW Press, JW Friedberg. <i>Haematologica</i> , pending revision/resubmission.		
S0016	Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus Rituximab or CHOP plus 131Iodine-Tositumomab - long term follow-up of phase III randomized study SWOG-S0016. M Shadman, H Li, L Rimsza, JP Leonard, MS Kaminski, RM Braziel, CM Spier, AK Gopal, DG Maloney, B Cheson, S Dakhil, M LeBlanc, SM Smith, RI Fisher, JW Friedberg, OW Press. <i>Journal of Clinical Oncology</i> , resubmitted.		
S0410	Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent hodgkin lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network phase II Trial (SWOG S0410/BMT CTN 0703). EP Smith, H Li, JW Friedberg, LS Constine, LM Rimsza, JR Cook, GG Laport, LL Popplewell, L A Holmberg, SM Smith, M LeBlanc, SJ Forman, R Fisher, PJ Stiff. <i>Biology of Blood and Marrow Transplantation</i> , pending revision and resubmission.	10/15/05	2/1/09

- S0801 Phase 2 study of RCHOP, radioimmunotherapy and maintenance rituximab in untreated follicular lymphoma: SWOG S0801. PM Barr1, H Li, WR Burack, M LeBlanc, SM Smith, AK Gopal, JD Floyd, DO Persky, OW Press, RI Fisher, JW Friedberg. Lancet Haematology, submitted .
- S0806 A phase i/ii trial of vorinostat (SAHA) in combination with rituximab-chop in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. DO Persky, H Li, LM Rimsza, PM Barr, LL Popplewell, CL Bane, A Von Gehr, M LeBlanc, RI Fisher, SM Smith, JW Friedberg. American Journal of Hematology, submitted.
- C50604 Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on interim FDG-PET for non-bulky stage I and II hodgkin lymphoma. DJ Straus, S-H Jung, B Pitcher, L Kostakoglu, JC Grecula, ED Hsi, H Schöder, LL Popplewell, JE Chang, CH Moskowitz, N Wagner-Johnson, JP Leonard, JW Friedberg, BS Kahl, BD Cheson, NL Bartlett. Journal of Clinical Oncology, submitted 9/5/17.
- CTSU 9177 Multicenter phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. K Dunleavy, MA Fanale, JS Abramson, A Noy, P Fabrizio Caimi, S Pittaluga, S Parekh, A Lacasce, JW Hayslip, D Jagadeesh, S Nagpal, MJ Lechowicz, R Gaur, JW Leach, A Lucas, C Melani, M Roschewski, SM Steinberg, ES Jaffe, B Kahl, JW Friedberg, RF Little, NL Bartlett, WH Wilson. Blood, submitted.

LYMPHOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017)

- S0816 The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial. DW Scott, H Li, Y Harvey, F Chun Chan, A Mottok, M Boyle, AM Evens, H Schoder, DJ Straus, NL Bartlett, JW Sweetenham, PM Barr, MA Fanale, ED Hsi, JR Cook, BS Kahl, JP Leonard, JW Friedberg, M LeBlanc, C Steidl, RD Gascoyne, LM Rimsza, OW Press. International Conference on Malignant Lymphoma (June 14-17, 2017, Lugano, Switzerland) oral presentation. Hematological Oncology, Volume 35, Issue Supplement S2 June 2017, pages 92–93.
http://onlinelibrary.wiley.com/doi/10.1002/hon.2437_81/full
- CTSU9177 Risk-adapted therapy in adults with burkitt lymphoma: updated results of a multicenter prospective phase II study of DA-EPOCH-R. K Dunleavy, M Roschewski, JS Abramson, A LaCasce, B Link, S Parekh, D Jagadeesh, S Nagpal, P Bierman, R Mitsuyasu, R Battini, PR Watson, D Peace, BJ Averbrook, H Naina, JW Leach, W Hanna, B Powell, C Melani, A Lucas, SM Steinberg, B Kahl, JW Friedberg, RF Little, NL Bartlett, MA Fanale, A Noy, WH Wilson. International Conference on Malignant Lymphoma (June 14-17, 2017, Lugano, Switzerland), oral presentation. Hematological Oncology, Volume 35, Issue Supplement S2 June 2017 pages 133–134.
http://onlinelibrary.wiley.com/doi/10.1002/hon.2437_122/full

LYMPHOMA ABSTRACTS SUBMITTED (2017)
(embargoed)

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2016)			
S0016/Other	Recommendations for clinical trial development in follicular lymphoma. K Maddocks, PM Barr, BD Cheson, RF Little, L Baizer, BS Kahl, JP Leonard, N Fowler, LI Gordon, BK Link, JW Friedberg, SM Ansell. <u>Journal of the National Cancer Institute</u> , Dec 31;109(3) pii: djw255, 2016. PMID: 28040699 [PMC n/a - Review] https://www.ncbi.nlm.nih.gov/pubmed/28040699	3/1/01	10/2/08
S0520	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive b-cell lymphomas: SWOG S0520. S Puvvada, H Li, DO Persky, SH Bernstein, RI Fisher, M LeBlanc, M Schmelz, B Glinsmann-Gibson, TP Miller, Anne-Marie Maddox, JW Friedberg, SM Smith, LM Rimsza. <u>Leukemia & Lymphoma</u> , Oct;57(10):2359-2369, 2016. 2016 Jan 12;1-11. [Epub ahead of print]; PMID26758422; PMC5140034 http://www.ncbi.nlm.nih.gov/pubmed/26758422	1/1/06	5/1/09
S0601	Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for mantle cell lymphoma: SWOG S0601. BG Till, H Li, SH Bernstein, RI Fisher, WR Burack, LM Rimsza, JD Floyd, MA DaSilva, DF Moore, Jr., O Pozdnyakova, SM Smith, M LeBlanc, JW Friedberg. <u>British Journal of Haematology</u> , Jan; 172(2):208-218, 2016. 2015 Oct 22 [Epub ahead of print]. PMID26492567; PMC4710555 http://www.ncbi.nlm.nih.gov/pubmed/26492567	8/15/06	6/1/08
S0816	A US intergroup trial of response-adapted therapy of stage III–IV hodgkin lymphoma using early interim FDG–PET imaging (SWOG S0816). OW Press, H Li, H Schöder, CH Moskowitz, DJ Straus, M LeBlanc, LM Rimsza, NL Bartlett, AM Evens, ES Mittra, AS LaCasce, JW Sweetenham, PM Barr, MA Fanale, MV Knopp, A Noy, ED Hsi, JR Cook, M Lechowicz, RD Gascoyne, JP Leonard, BS Kahl, BD Cheson, RI Fisher, JW Friedberg. <u>Journal of Clinical Oncology</u> , Jun 10;34(17):2020-2027, 2016; 2016 Apr 11 [Epub ahead of print]. PMID27069074; PMC4966513 http://www.ncbi.nlm.nih.gov/pubmed/27069074	7/1/09	12/1/12
S0816	Reply to H.J.A. Adams et al and E.A. Hawkes et al. [correspondence re S0816] O Press, J Friedberg. <u>Journal of Clinical Oncology</u> , DOI: 10.1200/JCO.2016.69.7979; [online before print October 28, 2016] PMID27069074; PMC n/a http://ascopubs.org/doi/pdf/10.1200/JCO.2016.69.7979	7/1/09	12/1/12

S0816	Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin Lymphoma (HL): a sub-analysis of SWOG S0816 phase 2 trial. A Danilov, H Li, OW Press, I Shapira, LJ Swinnen, A Noy, E Reid, SM Smith, JW Friedberg. <u>Leukemia & Lymphoma</u> Jul 7:1-5. [Epub ahead of print]. PMID27386786; PMC5130311 http://www.ncbi.nlm.nih.gov/pubmed/27386786	7/1/09	12/1/12
S0816/Other	Hodgkin lymphoma: Current status and clinical trial recommendations. CS Diefenbach, JM Connors, JW Friedberg, JP Leonard, BS Kahl, RF Little, L Baizer, AM Evens, RT Hoppe, KM Kelly, DO Persky, A Younes, L Kostakaglu, NL Bartlett. <u>Journal of the National Cancer Institute</u> , Dec 31;109(4). pii: djw249, 2016. PMID28040700; PMC n/a – Review. https://www.ncbi.nlm.nih.gov/pubmed/28040700		
S8736	Continued risk of relapse independent of treatment modality in limited stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG Study S8736. DM Stephens, ML LeBlanc, H Li, SD Puvvada, D Persky, JW Friedberg, SM Smith. <u>Journal of Clinical Oncology</u> , Sep 1;34(25): 2997-3004, 2016. 2016 Jul 5 [Epub ahead of print]. PMID27382104; PMC5012710 http://www.ncbi.nlm.nih.gov/pubmed/27382104	3/15/88	6/15/95
S9704	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup S9704. SD Puvvada, PJ Stiff, M Leblanc, JR Cook, S Couban, JP Leonard, B Kahl, Deborah Marcellus, TC Shea, JN Winter, H Li, LM. Rimsza, JW Friedberg, SM Smith. <u>British Journal of Haematology</u> , Sep;174(5):686-691, 2016. 2016 Apr 13 [Epub ahead of print]. PMID27072903; PMC5125530 http://www.ncbi.nlm.nih.gov/pubmed/27072903	9/5/97	12/15/07
BMT/CTN 0701	Reduced intensity conditioning with high dose RTX yields excellent outcomes after allogeneic hematopoietic cell transplantation for relapsed follicular lymphoma: a phase II multicenter trial from the Blood and Marrow Transplant Network. GG Laport, J Wu, B Logan, V Bachanova, C Hosing, T Fenske, W Longo, SM Devine, A Nademanee, I Gersten, M Horowitz, HM Lazarus, ML Riches [néeTomblyn]. <u>Biology of Blood and Marrow Transplantation</u> Aug;22(8):1440-1448, 2016 . 2016 Apr 23 [Epub ahead of print]. PMID27118571; PMC4949103 http://www.ncbi.nlm.nih.gov/pubmed/27118571	4/1/09	10/1/12
E4494	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD, Peterson BA <u>Leukemia & Lymphoma</u> 2016 Dec 14:1-9. PMID27967294 https://www.ncbi.nlm.nih.gov/pubmed/27967294		

- Multiple*/Other Recommendations for clinical trial development in mantle cell lymphoma. SE Spurgeon, BG Till, P Martin, AH Goy, MP Dreyling, AK Gopal, M LeBlanc, JP Leonard, JW Friedberg, L Baizer, RF Little, BS Kahl, MR Smith. Journal of the National Cancer Institute, 2016 Dec 31;109(1). pii: djw263. PMID28040733
*studies S0601, S0213, S0108
<https://www.ncbi.nlm.nih.gov/pubmed/28040733>
- Multiple*/Other T-cell lymphoma: recent advances in characterization and new opportunities for treatment. C Casulo, O O'Connor, A Shustov, M Fanale, JW Friedberg, JP Leonard, BS Kahl, RF Little, L Pinter-Brown, R Advani, S Horwitz. Journal of the National Cancer Institute, 2016 Dec 31;109(2). pii: djw248. PMID28040682
[*studies S0350, S1108]
<https://www.ncbi.nlm.nih.gov/pubmed/28040682>
- Multiple*/Other Beyond RCHOP: A blueprint for diffuse large B-cell lymphoma research. GS Nowakowski, KA Blum, BS Kahl, JW Friedberg, L Baizer, RF Little, DG Maloney, LH Sehn, ME Williams, WH Wilson, JP Leonard, SM Smith. Journal of the National Cancer Institute, 2016 Dec 16;108(12). pii: djw257.; PMID: 27986884; PMC n/a – Review. [*S9704, S0433, S0515]
<https://www.ncbi.nlm.nih.gov/pubmed/27986884>
- Study N/A General biomarker recommendations for lymphoma. L Rimsza, Y Fedoriw, LM Staudt, A Melnick, R Gascoyne, M Crump, L Baizer, K Fu, E Hsi, JWC Chan, L McShane, JP Leonard, BS Kahl, RF Little, JW Friedberg, L Kostakoglu. Journal of the National Cancer Institute, 2016 Dec 16;108(12). pii: djw250. Print 2016 Dec. PMID27986882
<https://www.ncbi.nlm.nih.gov/pubmed/27986882>

LYMPHOMA ABSTRACTS PUBLISHED/PRESENTED (2016)

- | | | | |
|-------|--|--------|---------|
| S0016 | Molecular characterization of follicular lymphoma patients enrolled on SWOG S0016 using FFPE Chromosomal Genomic Array Testing. X Qu, H Li, O Press, L Rimsza, R Braziel, M LeBlanc, E Hsi, S Smith, J Friedberg, M Fang. 2016 Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (March 8-12, 2016, Tampa, FL), poster presentation (Abstract #141). | 3/1/01 | 10/2/08 |
| S0016 | Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus rituximab or CHOP plus (131) iodine-tositumomab - long term follow-up of phase III randomized study SWOG S0016. M Shadman, H Li, L Rimsza, P Leonard, MS Kaminski, RM Braziel, CM Spier, AK Gopal, DG Maloney, BD Cheson, S Dakhil, M LeBlanc, SM Smith, RI Fisher, JW Friedberg, OW Press. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <u>Blood</u> 126(23): 2678, 2016.
http://www.bloodjournal.org/content/126/23/2678 | 3/1/01 | 10/2/08 |

S0801	Sequential RCHOP, radioimmunotherapy and rituximab maintenance improves early outcomes in advanced stage follicular lymphoma: 5 year outcomes from SWOG 0801. PM Barr, H Li, WR Burack, M LeBlanc, SM Smith, AK Gopal, JD Floyd, DO Persky, OW Press, RI Fisher, JW Friedberg. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <u>Blood</u> 128:614, 2016. http://www.bloodjournal.org/content/128/22/614	4/1/09	12/15/10
S0816	Long-term follow-up of SWOG S0816: Response-adapted therapy of advanced stage Hodgkin lymphoma using early interim FDG-PET imaging. JW Friedberg, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, LM Rimsza, NL Bartlett, AM Evens, ES Mittra, AS LaCasce, JW Sweetenham, PM Barr, MA Fanale, MV Knopp, A Noy, ED Hsi, JR Cook, MJ Lechowicz, RD Gascoyne, JP Leonard, BS Kahl, BD Cheson, RI Fisher, OW Press. International Symposium on Hodgkin Lymphoma (Oct 22-25, 2016, Cologne, Germany), oral presentation; <u>Haematologica</u> October 2016 101:19 (abst T003). http://www.haematologica.org/content/101/s5/1.full.pdf+html	7/1/09	12/1/12
S9704	Autologous transplantation as consolidation for high risk aggressive t-cell non-Hodgkin's lymphoma: a SWOG S9704 intergroup trial subgroup analysis. PJ Stiff, H Li, JR Cook, LS Constine, S Couban, DA Stewart, TC Shea, P Porcu, JN Winter, BS Kahl, SM Smith, D Marcellus, KP Barton, GM Mills, M LeBlanc, LM Rimsza, SJ Forman, JP Leonard, RI Fisher, JW Friedberg. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:4651, 2016. http://www.bloodjournal.org/content/128/22/4651	9/5/97	12/15/07
C50303	Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large b-cell lymphoma: (Alliance) CALGB 50303. WH Wilson, S-H Jung, B Pitcher, E Hsi, RI Fisher, BD Cheson, N Bartlett, S Smith, NW Johnston, BS Kahl, L Staudt, K Blum, J Abramson, OW Press, J Friedberg, A Zelenetz, JP Leonard. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <u>Blood</u> 128:469, 2016. http://www.bloodjournal.org/content/128/22/469	9/15/06	5/8/13
E2496	Serum biomarkers predict outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. JA Kanakry, F Hong, O Martinez-Maza, SJ Horning, LI Gordon, RD Gascoyne, LL Gellert, M Lemas, BD Cheson, RH Advani, B Pohlman, L Teston, VP Kenkre, JN Winter, PJ Stiff, JM Tuscano, JW Friedberg, J Polikoff, LM Dreosti, JP Kuebler, S Robinson, DS Morgan, RI Fisher, NL Bartlett, P Laneuville, BS Kahl, RF Ambinder. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:2992, 2016. http://www.bloodjournal.org/content/128/22/2992	6/15/99	6/15/06

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2015)			
S0313	Effect of adding tiuxetan (zevallin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive b-cell lymphoma (SWOG 0313). DO Persky, TP Miller, JM Unger, CM Spier, S Puvvada, B Dino Stea, OW Press, LS. Constine, KP Barton, JW Friedberg, RI Fisher. <u>Blood</u> Jan 8;125(2):236-41, 2015. PMID25395425; PMC4287635 http://www.ncbi.nlm.nih.gov/pubmed/25395425	2/1/04	12/15/08
S0601	Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for mantle cell lymphoma: SWOG S0601. BG Till, H Li, SH Bernstein, RI Fisher, WR Burack, LM Rimsza, JD Floyd, MA DaSilva, DF Moore, Jr., O Pozdnyakova, SM Smith, M LeBlanc, JW Friedberg. <u>British Journal of Haematology</u> , 2015 Oct 22 [Epub ahead of print]. PMID26492567; NIHMS734420; PMC pending http://www.ncbi.nlm.nih.gov/pubmed/26492567	8/15/06	6/1/08
S1108	Phase II intergroup trial of alisertib in relapsed and refractory transformed and peripheral T-cell non-Hodgkin lymphoma and transformed mycosis fungoides: SWOG 1108. PM Barr, H Li, C Spier, D Mahadevan, M LeBlanc, M Ul-Haq, BD Huber, CR Flowers, ND Wagner-Johnston, SM Horwitz, RI Fisher, BD Cheson, SM Smith, BS Kahl, N Bartlett, JW Friedberg. <u>Journal of Clinical Oncology</u> Jul 20;33(21):2399-2404, 2015; 2015 Jun 15 [Epub ahead of print]. PMID26077240; PMC4500834 http://www.ncbi.nlm.nih.gov/pubmed/26077240	10/28/11	6/6/13
E2496	Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stage I or II locally extensive, bulky mediastinal hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. RH Advani, F Hong, RI Fisher, NL Bartlett, S Robinson, RD Gascoyne, H Wagner, Jr., PJ Stiff, BD Cheson, D Stewart, LI Gordon, BS Kahl, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, RT Hoppe, SJ Horning. <u>Journal of Clinical Oncology</u> Jun 10;33(17):1936-1942, 2015. PMID25897153; PMC4451176 http://www.ncbi.nlm.nih.gov/pubmed/25897153	6/15/99	6/15/06

E2496	Evaluation of the International Prognostic Score (IPS) and a new prognostic index for patients with advanced hodgkin lymphoma treated on US Intergroup E2496. C Diefenbach, H Li, F Hong, LI Gordon, RI Fisher, NL Bartlett, RM Crump, RD Gascoyne, H Wagner, P Stiff, B Cheson, D Stewart, BS Kahl, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, RT Hoppe, SJ Horning, RH Advani. <u>British Journal of Haematology</u> , Nov;171(4):530-538, 2015. PMID26343802; PMC pending. http://www.ncbi.nlm.nih.gov/pubmed/26343802	6/15/99	6/15/06
Multiple*	Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma. M Mir, MJ Maurer, SC Ziesmer, S Slager, T Habermann, W Macon, BK Link, S Syrbu, T Witzig, J Friedberg, O Press, M LeBlanc, JR Cerhan, A Novak, S Ansell. <u>Blood</u> Feb 5; 125(6):992-998, 2015. PMID25422100; PMC4319239. Studies include: SWOG S9800, S9911, S0016. http://www.ncbi.nlm.nih.gov/pubmed/25422100	n/a	n/a
Multiple*	Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. JL Kelly, G Salles, B Goldman, RI Fisher, O Casasnovas, OW Press, DG Maloney, P Soubeyran, LM Rimsza, M LeBlanc, H Tilly, JW Friedberg. <u>Journal of Clinical Oncology</u> May 1;33(13):1482-1490; 2015 Mar 30.[Epub ahead of print]. PMID25823738; PMC4404425 *Studies: S9800, S9911, S0016B, S8947. http://www.ncbi.nlm.nih.gov/pubmed/25823738		

LYMPHOMA MANUSCRIPTS SUBMITTED (2015)

S0520	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive b-cell lymphomas: SWOG S0520. S Puvvada, H Li, DO Persky, SH Bernstein, RI Fisher, M LeBlanc, M Schmelz, B Glinsmann-Gibson, TP Miller, Anne-Marie Maddox, JW Friedberg, SM Smith, LM Rimsza. <u>Leukemia & Lymphoma</u> , under review.	1/1/06	5/1/09
S0816	A US intergroup trial of response-adapted therapy of stage III–IV hodgkin lymphoma using early interim FDG–PET imaging (SWOG S0816). OW Press, H Li, H Schöder, CH Moskowitz, DJ Straus, M LeBlanc, LM Rimsza, NL Bartlett, AM Evens, ES Mittra, AS LaCasce, JW Sweetenham, PM Barr, MA Fanale, MV Knopp, A Noy, ED Hsi, JR Cook, M Lechowicz, RD Gascoyne, JP Leonard, BS Kahl, BD Cheson, RI Fisher, JW Friedberg. <u>Journal of Clinical Oncology</u> , under review.	7/1/09	12/1/12
S8736	Continued risk of relapse independent of treatment modality in limited stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG Study S8736. DM Stephens, ML LeBlanc, H Li, TP Miller, SD Puvvada, D Persky, JW Friedberg, SM Smith. <u>Journal of Clinical Oncology</u> , pending revision and resubmission 12/15.	3/15/88	6/15/95

S9704	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: Subset analysis of randomized trial intergroup S9704. SD Puvvada, PJ Stiff, M Leblanc, JR Cook, S Couban, JP Leonard, B Kahl, Deborah Marcellus, TC Shea, JN Winter, H Li, LM Rimsza, JW Friedberg, SM Smith. <u>British Journal of Haematology</u> , under review.	9/5/97	12/15/07
BMT/CTN 0701	Reduced intensity conditioning with high dose RTX yields excellent outcomes after allogeneic hematopoietic cell transplantation for relapsed follicular lymphoma: a phase II multicenter trial from the blood and marrow transplant network (BMT CTN). GG Laport, J Wu, B Logan, V Bachanova, C Hosing, T Fenske, W Longo, SM Devine, A Nademanee, I Gersten, M Horowitz, HM Lazarus, ML Riches [néeTomblyn]. <u>Journal of Clinical Oncology</u> , under review.	4/1/09	10/1/12

LYMPHOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2015)

S0016	Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG Study S0016. X Qu, H Li, O Press, L Rimsza, R Braziel, M LeBlanc, E Hsi, SM Smith, JW Friedberg, M Fang. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), poster presentation; <u>Blood</u> 2015 126(23):2678, 2015. http://www.bloodjournal.org/content/126/23/2678	3/1/01	10/2/08
S0806	A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large b-cell lymphoma (DLBCL): SWOG S0806. DO Persky, H Li, LM Rimsza, PM Barr, LL Popplewell, CL Bane, A Von Gehr, M LeBlanc, RI Fisher, SM Smith, JW Friedberg. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), poster; <u>Blood</u> 126(23):3931, 2015. http://www.bloodjournal.org/content/126/23/3931	11/15/10	10/1/13
S0816	Feasibility of interim PET-adapted therapy in HIV-positive patients with advanced Hodgkin Lymphoma (HL) – sub-analysis of SWOG S0816 phase 2 trial. A Danilov, H Li, OW Press, I Shapira, L Swinnen, A Noy, E Reid, S Smith, JW Friedberg. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), poster; <u>Blood</u> 126(23): 1498, 2015. http://www.bloodjournal.org/content/126/23/1498?sso-checked=true	7/1/09	12/1/12
S1106	Results of a randomized phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma: US intergroup study S1106. R Chen, H Li, SH Bernstein, LM Rimsza, SJ Forman, LS Constine, TC Shea, AF Cashen, K Blum, TS Fenske, PM Barr, M Leblanc, RI Fisher, SM Smith, JW Friedberg. International Conference on Malignant Lymphoma (June 17-20, 2015, Lugano, Switzerland), oral presentation; <u>Hematological Oncology</u> 33: (Suppl S1, abst. 062) p.132, 2015. http://onlinelibrary.wiley.com/doi/10.1002/hon.2227/epdf	10/1/11	6/26/13

S1106	Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma. R Chen, H Li, SH Bernstein, LM Rimsza, SJ Forman, LS Constine, TC Shea, AF Cashen, K Blum, TS Fenske, PM Barr, M Leblanc, RI Fisher, BD Cheson, SM Smith, M Faham, J Wilkins, JP Leonard, BS Kahl, JW Friedberg. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral; <u>Blood</u> 126(23):518, 2015. http://www.bloodjournal.org/content/126/23/518	10/1/11	6/26/13
S8736	Chemotherapy + radiation and chemotherapy alone in limited stage diffuse large B-cell lymphoma (DLBCL): Final and long-term analysis of SWOG Study S8736. DM Stephens, ML LeBlanc, H Li, TP Miller, SD Puvvada, D Persky, JW Friedberg, SM Smith. International Conference on Malignant Lymphoma (June 17-20, 2015, Lugano, Switzerland), accepted, oral presentation; Hematological Oncology 33: (Suppl S1, abst. 128) p.170, 2015. http://onlinelibrary.wiley.com/doi/10.1002/hon.2227/epdf	3/15/88	6/15/95
C50604	Results of US intergroup trial of response-adapted chemotherapy based on PET for non-bulky stage I and II hodgkin lymphoma (HL) (CALGB/Alliance 50604). DJ. Straus, BN Pitcher, L Kostakoglu, JC Grecula, E Hsi, H Schöder, S-H Jung, LL Popplewell, JP Leonard, JW Friedberg, BS Kahl, BD Cheson, NL Bartlett, MD. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral; <u>Blood</u> 126(23):578, 2015. http://www.bloodjournal.org/content/126/23/578	8/1/10	2/21/13
CTSU9177	Risk-adapted low-intensity therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R. K Dunleavy, A LaCasce, B Link, S Parekh, D Jagadeesh, R Lord, P Bierman, R Mitsuyasu, R Battini, PR Watson, D Peace, BJ Averbrook, H Naina, JW Leach, W Hanna, B Powell, M Roschewski, A Lucas, SM Steinberg, B Kahl, JW Friedberg, RF Little, NL Bartlett, MA Fanale, WH Wilson. American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral presentation; <u>Blood</u> 126(23):342, 2015.4 http://www.bloodjournal.org/content/126/23/342?sso-checked=true	5/15/12	n/a
None (SWOG/ Hope Fdn)	The impact of HBO on early ALC recovery following high-dose therapy and autologous transplantation. [SWOG/Hope Foundation Pilot Study]. O Aljitawi, M Markiewicz, A Seng, T Lin, S Ganguly, J Mahnken, A Singh, L Shune, SH Abhyankar, B Lipe, D Allin, J McGuirk, T Yankee. ASCO Annual Meeting (5/29-6/2/15, Chicago, IL), poster session. <u>J Clin Oncol</u> 33, 2015 (suppl; abstr 7034). http://meetinglibrary.asco.org/content/152028-156	n/a	n/a

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2014)			
S0313	Effect of adding tiuxetan (zevallin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive b-cell lymphoma (SWOG 0313). DO Persky, TP Miller, JM Unger, CM Spier, S Puvvada, B Dino Stea, OW Press, LS. Constine, KP Barton, JW Friedberg, RI Fisher. <u>Blood</u> 2014 Nov 13 [Epub ahead of print]. PMID25395425; PMC Journal – In Process. http://www.ncbi.nlm.nih.gov/pubmed/25395425	2/1/04	12/15/08
S0433	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG protocol S0433. J Friedberg, J Unger, WR Burack, AJ Gopal, RN Raju, AP Nademanee, M Kaminski, M Leblanc, H Li, OW Press, TP Miller, RI Fisher. <u>British Journal of Haematology</u> , 166(3):382-389, 2014. PMID24749780; PMC4107050 http://www.ncbi.nlm.nih.gov/pubmed/24749780	11/1/05	3/1/10
S9704	The role of myeloablation for lymphoma. PJ Stiff, JM Unger, RI Fisher. <u>New England Journal of Medicine</u> 370(6):575-576, 2014. PMID24499218; [correspondence not within the scope of Public Access Policy] http://www.ncbi.nlm.nih.gov/pubmed/24499218	9/5/97	12/15/07
S9704	Clinical significance of MYC protein expression and/or high grade morphology in non-Burkitt, diffuse aggressive B-cell non-Hodgkin lymphomas: a SWOG S9704 correlative study. JR Cook, B Goldman, RR Tubbs, L Rimsza, M LeBlanc, P Stiff, RI Fisher. <u>American Journal of Surgical Pathology</u> , 38(4):494-501, 2014. PMID24625415; PMC3955880 http://www.ncbi.nlm.nih.gov/pubmed/24625415	9/5/97	12/15/07
Multiple*(ECOG)	The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. F Hong, TM Habermann, L I Gordon, H Hochster, RD Gascoyne, VA Morrison, RI Fisher, NL Bartlett, PJ. Stiff, BD Cheson, M Crump, S J Horning, BS Kahl. <u>Annals of Oncology</u> 25(3):669–674, 2014. *Studies E1496, E2496, E4494 PMID24567515 http://www.ncbi.nlm.nih.gov/pubmed/24567515		

Multiple*	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. HL Gustafson, S Yao, B Goldman, K Lee, C Spier, M LeBlanc, L Rimsza, JR Cerhan, TM Habermann, BK Link, MJ Maurer, SL Slager D Persky, T Miller, RI Fisher, C Ambrosone, M Briehl. <u>American Journal of Hematology</u> 89(6):639-645, 2014. [studies S0014, S8516, S8736, S9125, S9240, S9349, S9704].PMID24633940; PMC4137041 http://www.ncbi.nlm.nih.gov/pubmed/24633940	n/a	n/a
Multiple*	Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma. M Mir, MJ Maurer, SC Ziesmer, S Slager, T Habermann, W Macon, BK Link, S Syrbu, T Witzig, J Friedberg, O Press, M LeBlanc, JR Cerhan, A Novak, S Ansell. <u>Blood</u> 2014 Nov 24 [Epub ahead of print]. PMID25422100; PMC Journal – In Process. Studies include: SWOG S9800, S9911, S0016.	n/a	n/a

LYMPHOMA MANUSCRIPTS SUBMITTED (2014)

Multiple*	Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. JL Kelly, G Salles, B Goldman, RI Fisher, O Casasnovas, OW Press, DG Maloney, P Soubeyran, LM Rimsza, M LeBlanc, H Tilly, JW Friedberg. <u>Journal of Clinical Oncology</u> , revised/resubmitted. *Studies: S9800, S9911, S0016, S8947.		
E2496	Randomized phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II locally extensive (bulky mediastinal) hodgkin lymphoma: a subset analysis of the US intergroup trial E2496. RH Advani, F Hong, RI Fisher, NL Bartlett, S Robinson, RD Gascoyne, H Wagner, Jr., PJ Stiff, BD Cheson, D Stewart, LI Gordon, BS Kahl, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, RT Hoppe, SJ Horning. <u>Journal of Clinical Oncology</u> , under review.	6/15/99	6/15/06
E2496	Evaluation of the International Prognostic Score (IPS) and a new prognostic index for patients with advanced hodgkin lymphoma treated on US Intergroup E2496. C Diefenbach, H Li, F Hong, LI Gordon, RI Fisher, NL Bartlett, RM Crump, RD Gascoyne, H Wagner, P Stiff, B Cheson, D Stewart, BS Kahl, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, RT Hoppe, SJ Horning, RH Advani. <u>Blood</u> , submitted 11/26/14; under review.	6/15/99	6/15/06

LYMPHOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2014)

S0016/Multiple	Elevated MIG, IL-2R and IL1-R1 are associated with early progression in in follicular lymphoma. M Mir, M Maurer, SC Ziesmer, S Slager, T Haberman, BK Link, T Witzig, J Friedberg, O Press, M Leblanc, JR Cerhan, A Novak, S Ansell. ASH Lymphoma Biology Conference (August 10-13, Colorado Springs, CO), poster presentation.	3/1/01	10/2/08
S0313	Long term follow up of SWOG S0313: Ibritumomab Tiuxetan consolidation after 3 cycles of CHOP plus radiotherapy for high risk limited stage aggressive B-cell lymphoma. DO Persky, TP Miller, JM Unger, CM Spier, S Puvvada, BD Stea, OW Press, LS Constine, KP Barton, M LeBlanc, S Smith, RI Fisher, JW Friedberg. American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster presentation.	2/1/04	12/15/08
S0410	SWOG S0410/CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987). EP Smith, H Li, JW Friedberg, LS Constine, LM Rimsza, GG Laport, LL Popplewell, DG Maloney, M Leblanc, SJ Forman, RI Fisher, PJ Stiff. American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral presentation.	10/15/05	2/1/09
S0601	Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. BG Till, H Li, SH Bernstein, RI Fisher, WR Burack, LM Rimsza, JD Floyd, MA DaSilva, DF Moore, Jr, M LeBlanc, JW Friedberg. American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral presentation.	8/15/06	6/1/08
S1108	US Intergroup Phase II Trial (SWOG S1108) of Alisertib, an Investigational Aurora A Kinase (AAK) Inhibitor, in patients with Peripheral T-Cell Lymphoma (PTCL) (NCT01466881). PM Barr, H Li, C Spier, D Mahadevan, JW Friedberg, M LeBlanc, M Ul Haq, CR Flowers, N Wagner-Johnston, SM Horwitz, B Cheson, TP Miller, RI Fisher. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 8523), 2014. http://abstracts.asco.org/144/AbstView_144_129433.html	10/28/11	6/6/13
S9704	Double hit lymphoma and double positive lymphoma: subset analyses of MYC positive patients of SWOG S9704. S Puvvada, PJ Stiff, M Leblanc, JR Cook, BS Kahl, L Hongli, L Rimsza, JW Friedberg, SM Smith. American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster presentation.	9/5/97	12/15/07

CTSU/9177	Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. K Dunleavy, MA Fanale, A LaCasce, A Noy, P Fabrizio Caimi , S Parekh, JW Hayslip, AS Advani, R Sterling Lord, MJ Lechowicz, R Gaur, JW Leach, A Lucas, S Steinberg, B Kahl, JW Friedberg, RF Little, N Bartlett, WH Wilson. American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral presentation.	5/15/12	n/a
-----------	--	---------	-----

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED (2013)			
S0016	A phase III randomized intergroup trial of CHOP chemotherapy plus rituximab compared to CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkins lymphoma (SWOG S0016). OW Press, JM Unger, L Rimsza, JW Friedberg, M LeBlanc, M Czuczman, M Kaminski, R Brazier, C Spier, AK Gopal, DG Maloney, B Cheson, S Dakhil, TP Miller, RI Fisher. <u>Journal of Clinical Oncology</u> , 31(3):314-320, 2013. PMID23233710; PMC3732010 http://www.ncbi.nlm.nih.gov/pubmed/23233710	3/1/01	10/2/08
S0016	A comparative analysis of prognostic factor models for for follicular lymphoma based on a phase III trial of CHOP-Rituximab vs CHOP + 131Iodine-Tositumomab. OW Press, JM Unger, LM Rimsza, JW Friedberg, M LeBlanc, MS Czuczman, M Kaminski, RM Brazier, C Spier, AK Gopal, DG Maloney, BD Cheson, SR Dakhil, TP Miller, RI Fisher. <u>Clinical Cancer Research</u> 19(23):6624-6632, 2013. PMID24130072; PMC3872052 http://www.ncbi.nlm.nih.gov/pubmed/24130072	3/1/01	10/2/08
S0213	A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients $\leq$ 70 years of age with previously untreated mantle cell lymphoma: SWOG 0213. S Bernstein, E Epner, J Unger, M LeBlanc, E Cebula, WR Burack, L Rimsza, T Miller, RI Fisher. <u>Annals of Oncology</u> , 24(6):1587-1593; 2013. PMID23504948; PMC3660082 http://www.ncbi.nlm.nih.gov/pubmed/23504948	10/1/02	9/1/06
S0350	Phase II trial of cisplatin plus etoposide plus gemcitabine plus solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). D Mahadevan, J Unger, C Spier, D Persky, F Young, M LeBlanc, RI Fisher, TP Miller. <u>Cancer</u> 119(2):371-379, 2013. PMID22833464;PMC3485430 http://www.ncbi.nlm.nih.gov/pubmed/22833464	9/15/05	12/1/10
S9704	Autologous transplant as consolidation for aggressive non-hodgkin's lymphoma. P Stiff, J Unger, J Cook, L Constine, S Couban, D Stewart, T Shea, P Porcu, J Winter, B Kahl, T Miller, R Tubbs, D Marcellus, J Friedberg, K Barton, G Mills, M LeBlanc, L Rimsza, S Forman, RI Fisher. <u>New England Journal of Medicine</u> , 369(18):1681-1690, 2013. PMID:24171516; NIHMSID#542780 http://www.ncbi.nlm.nih.gov/pubmed/?term=stiff+p+Autologous+transplant+as+consolidation+for+aggressive	9/5/97	12/15/07
BMT/CTN 0401	Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tositumomab/BEAM with autologous stem cell transplantation for relapsed diffuse large b-cell lymphoma	4/1/09	10/1/12

	(DLBCL): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0401 trial. J Vose, S Carter, LJ Burns, E Ayala, O Press, C Moskowitz, E Stadtmauer, S Mineshi, R Ambinder, T Fenske, M Horowitz, RI Fisher, M Tomblyn. <u>Journal of Clinical Oncology</u> 31(13):1662-1668, 2013 PMID23478060; PMC3635682 http://www.ncbi.nlm.nih.gov/pubmed/23478060		
E2496	Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classic al hodgkin lymphoma. DW Scott, FC Chan, F Hong, S Rogic, K Tan, B Meissner, S Ben-Neriah, M Boyle, R Kridel, A Telenius, B Woolcock, P Farinha, RI Fisher, L Rimsza, NL Bartlett, L Shepherd, RH Advani, JM Connors, BS Kahl, LI Gordon, SJ Horning, C Steidl, RD Gascoyne. <u>Journal of Clinical Oncology</u> 31(6):692-700, 2013. PMID23182984; PMC3574267 http://www.ncbi.nlm.nih.gov/pubmed/23182984	6/15/99	6/15/06
E2496	The efficacy and tolerability of ABVD and Stanford V in elderly hodgkin lymphoma from US intergroup trial. AM Evens, F Hong, L Gordon, RI Fisher, P Stiff, T Miller, N Bartlett, J Connors, R Gascoyne, H Wagner, M Gospodarowicz, B Cheson, R Advani, R Hoppe, B Kahl, S Horning. <u>British Journal of Haematology</u> 161(1):76-86, 2013 . PMID23356491; NIHMS431372 http://www.ncbi.nlm.nih.gov/pubmed/23356491	6/15/99	6/15/06
E2496	A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkins lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). L Gordon, F Hong, RI Fisher, NL Bartlett, JM Connors, R Gascoyne, H Wagner, P Stiff, B Cheson, M Gospodarowicz, R Advani, B Kahl, J Friedberg, K Blum, T Habermann, J Tuscano, RT Hoppe, SJ Horning. <u>Journal of Clinical Oncology</u> , 31(6):684-91, 3013. PMID23182987; PMC3574266 http://www.ncbi.nlm.nih.gov/pubmed/23182987	6/15/99	6/15/06
E2496	Plasma Epstein-Barr viral DNA as a marker of tumor response in Hodgkin lymphoma. JA Kanakry, H Li, LL Gellert, MV Lemas, W Hsieh, F Hong, KL Tan, R Gascoyne, LI Gordon, RI Fisher, NL Bartlett, P Stiff, B Cheson, R Advani, L Rimsza, B Hahl, SJ Horning. <u>Blood</u> , 121(18):3547-3553, 2013 . PMID23386127; PMC3643756 http://www.ncbi.nlm.nih.gov/pubmed/23386127	6/15/99	6/15/06

LYMPHOMA ABSTRACTS PUBLISHED (2013)

S0515	Markers of angiogenesis and hypoxia in germinal center B cell (GCB) and non-GCB subtypes of diffuse large B cell non-hodgkin lymphoma (DLBCL): correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab. B Ambuga, M Abu Zaid, J Unger, L Rimsza, M Marron, R Fisher, TP Miller, AT Stopeck. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), general poster discussion. <u>Journal of Clinical Oncology</u> 31(suppl; abstr 8562), 2013. http://abstracts2.asco.org/AbstView_132_115754.html	6/15/05	9/15/08
-------	---	---------	---------

S0816	A phase II trial of response-adapted therapy of stage III-IV hodgkin lymphoma using early interim FDG-PET imaging: SWOG S0816. OW Press, M LeBlanc, LM Rimsza, H Schoder, JW Friedberg, H Li, N Bartlett, A LaCasce, J Sweetenham, A Evens, M Knopp, A Noy, RD Gascoyne, BD Cheson, B Kahl, TP Miller, RI Fisher. International Conference on Malignant Lymphoma (June 19-22, 2013, Lugano, Switzerland), oral presentation; <u>Hematological Oncology</u> 31(suppl. 1): abstr. #24, p. 137. http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf	7/1/09	12/1/12
E2496	Evaluation of a novel 3 factor prognostic score (PS-3) for patients with advanced Hodgkin lymphoma (HL) treated on US Intergroup E2496. CS Diefenbach, H Li, F Hong, LI Gordon, RI Fisher, NL Bartlett, M Crump, RD Gascoyne, H Wagner, P Stiff, BD Cheson, D Stewart, B Kahl, JW Friedberg, KA Blum, T Habermann, J Tuscano, R Hoppe, SJ Horning, RH Advani. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; poster; Blood 122:4277, 2013 http://bloodjournal.hematologylibrary.org/content/122/21/4277.abstract?sid=24ad4745-3550-4002-80e3-d32b8200a9e9	6/15/99	6/15/06
E2496	Patterns of failure (POF) in a randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma (HL): an Intergroup study coordinated by the Eastern Cooperative Group (E2496). H Wagner, LI Gordon, F Hong, TJ Fitzgerald, F Laurie, RI Fisher, NL Bartlett, JM Connors, RD Gascoyne, P Stiff, B Cheson, M Gospodarowicz, R Advani, B Kahl, J Friedberg, K Blum, T Habermann, J Tuscano, R Hoppe, SJ Horning. International Conference on Malignant Lymphoma (June 19-22, 2013, Lugano, Switzerland), poster presentation. <u>Hematological Oncology</u> 31(suppl.1):abstr. #256, p. 182, 2013. http://onlinelibrary.wiley.com/doi/10.1002/hon.2058/pdf	6/15/99	6/15/06
E2496	Prospective evaluation of the utility of the international prognostic score (IPS) for patients with advanced Hodgkin lymphoma (HL) treated with contemporary therapy: results from US intergroup trial E2496. CS Diefenbach, H Li, RI Fisher, NL Bartlett, JM Connors, RD Gascoyne, H Wagner, PJ Stiff, BD Cheson, M Gospodarowicz, BS Kahl, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, RT Hoppe, SJ Horning, RH Advani. International Symposium on Hodgkin Lymphoma, (Oct 12-15, 2013, Cologne, Germany), submitted 5/29/13; poster presentation; <u>Haematologica</u> 98 (supplement 2):P010, CS, 4, 2013. http://www.haematologica.org/content/98/supplement_2/1.full.pdf+html	6/15/99	6/15/06
E4494	Elderly IPI (EIPI) in DLBCL patients > 60 years treated with R-CHOP: international validation study using data from RICOVER-60 (German High-Grade Non-Hodgkin Lymphoma Study Group) and LNH 98-5 (Groupe d'Etude de Lymphome d'Adultes). RH Advani, F Hong, TM Habermann, H Li, BS Kahl, VA Morrison, EA Weller, G Varma, RI Fisher, BA Peterson, B Cheson, RD Gascoyne, SJ Horning, S Bousetta, B Coiffier, M Ziepert, M Pfeundschuh. International Conference on Malignant Lymphoma (June 19-22, 2013, Lugano, Switzerland), poster presentation; <u>Hematological Oncology</u> 31(suppl.1):abstr.#222, p.171, 2013. http://onlinelibrary.wiley.com/doi/10.1002/hon.2058/pdf	11/15/99	7/12/01

- E4494 Improved risk stratification with addition of male sex (S) to the Elderly International Prognostic Index (S-EIPI) for DLBCL patients > 60 years treated with R-Chop: An international collaboration of the US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. R Advani, F Hong, T Habermann, H Li, BS Kahl, V Morrison, E Weller, G Varma, RI Fisher, BA Peterson, BD Cheson, RD Gascoyne, SJ Horning, S Boussetta, B Coiffier, M Ziepert, M Pfreundschuh. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation. Blood 122:3045, 2013.
<http://bloodjournal.hematologylibrary.org/content/122/21/3045.abstract?sid=c9b7f5f9-57f1-40dd-95f0-c9a5cc98ffdc>
- ECOG Multiple* The role of body mass index in survival outcome for lymphoma patients: an Eastern Cooperative Group Experience. F Hong, T Habermann, L Gordon, H Hochster, R Gascoyne, RI Fisher, N Bartlett, P Stiff, B Cheson, M Crump, S Horning, B Kahl. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation; Blood 122:3060, 2013. *Studies: E1496, E2496, E4494
<http://bloodjournal.hematologylibrary.org/content/122/21/3060.abstract?sid=d7ffe5a7-6c61-45ae-949b-b7e9728a2757>

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
--------------------	---------------------------------	-------------------------------	----------------------------

LYMPHOMA MANUSCRIPTS PUBLISHED (2012)

S0515	A phase II trial of R-CHOP plus bevacizumab for patients with newly diagnosed diffuse large b-cell non-hodgkin lymphoma: SWOG 0515. A Stopeck, JM Unger, LM Rimsza, M LeBlanc, B Farnsworth, M Iannone, MJ Glenn, RI Fisher, TP Miller. <u>Blood</u> 120(6):1210-1217, 2012. PMID22734071; PMIC3418716. http://www.ncbi.nlm.nih.gov/pubmed/22734071	6/15/05	9/15/08
S0517	A phase II study of vorinostat for treatment of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma; SWOG S0517. M Kirschbaum, B Goldman, J Zain, J Cook, L Rimsza, S Forman, R Fisher. <u>Leukemia & Lymphoma</u> , 53(2):259-262, 2012. PMID21823829; PMC3477846 http://www.ncbi.nlm.nih.gov/pubmed/21823829	9/15/05	8/1/07
S8809	Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemo-therapy but S9911 not chemotherapy alone. DO Persky, D Dornan, BH Goldman, RM Braziel, RI Fisher, M LeBlanc, DG Maloney, OW Press, TP Miller, LM Rimsza. <u>Haematologica</u> 97(6):937-942, 2012. PMID22271896; PMC3366663 http://www.ncbi.nlm.nih.gov/pubmed/22271896	10/1/88	11/15/94
S9900		2/5/98	11/15/98
S9911		5/15/99	6/1/00
E2496	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial. KL Tan, DW Scott, F Hong, B Kahl, RI Fisher, N Bartlett, RH Advani, R Buckstein, L Rimsza, JM Connors, C Steidl, L Gordon, S Horning, R Gascoyne. <u>Blood</u> 120(16):3280-3287, 2012. PMID22948049; PMC3476539 http://www.ncbi.nlm.nih.gov/pubmed/22948049	6/15/99	6/15/06

LYMPHOMA ABSTRACTS PUBLISHED/PRESENTED (2012)

S0016	A phase III randomized intergroup trial (S0016) comparing CHOP + rituximab vs. CHOP + iodine-131-tositumomab for front-line treatment of follicular lymphoma: subset analyses and comparison of prognostic models. O Press, J Unger, M LeBlanc, LM Rimsza, J Friedberg, MS Czuczman, MS Kaminski, R Braziel, C Spier, DG Maloney, BD Cheson, TP Miller, RI Fisher. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 8001). http://abstract.asco.org/AbstView_114_95376.html	3/1/01	10/2/08
-------	---	--------	---------

S0520	A phase II study of PDX101 (belinostat) in relapsed and refractory aggressive b-cell lymphomas (rel/ref ABCL): SWOG S0520. DO Persky, SH Bernstein, B Goldman, LM Rimsza, RI Fisher, TP Miller. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL); publication only. <i>J Clin Oncol</i> 30 (suppl; abstr e18536), 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=95361	1/1/06	5/1/09
S9704	MYC protein expression, but not high grade morphology, is associated with poor outcome in non-Burkitt diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. JR Cook, B Goldman, RR Tubbs, L Rimsza, M LeBlanc, P Stiff, R Fisher. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), oral presentation; <i>Blood</i> 120(21):abst. 543, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/585?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cook&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	9/15/97	12/15/07
E2496	Tumor-associated macrophages predict inferior outcomes in locally advanced and advanced stage classical hodgkins lymphoma – a correlative study from the E2496 intergroup trial. KL Tan, DW Scott, F Hong, SJ Horning, RI Fisher, NL Bartlett, L Shepherd, JM Connors, BS Kahl, LI Gordon, C Steidl, RD Gascoyne. United States and Canadian Academy of Pathology, annual meeting (March 17-23, 2012, Vancouver, BC, Canada), poster presentation, abst. #1568. http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1568	6/15/99	6/15/06
E4494	Differences in outcomes in males and females with diffuse Large B-cell lymphomas and follicular lymphoma treated with rituximab (ECOG E4494, CALGB 9793, SWOG E4494, E1496). T Habermann, F Hong, V Morrison, S Dakhil, SO Jacobson, JK Weick, S Frankel, R Gascoyne, R Fisher, B Cheson, EA Weller, BS Kahl, SJ Horning, BA Peterson, HS Hochster. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), accepted, poster presentation. <i>Blood</i> 120(21):abst. 3705, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3705?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=HABERMANN&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	11/15/99	7/12/01
Multiple*	Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation and replication in SWOG and LYSA. JL Kelly, G Salles, B Goldman, RI Fisher, O Casasnovas, O Press, D Maloney, P Soubeyran, L Rimsza, M LeBlanc, H Tilly, JW Friedberg. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), poster presentation; <i>Blood</i> 120(21):abst. 2712, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2712?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=serum+vitamin+d&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT *Studies: S0016, S8947, S9800, S9911.	n/a	n/a

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA ABSTRACTS PUBLISHED (2011)			
S0016	A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs. CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-hodgkin's lymphoma. OW Press, J Unger, L Rimsza, J Friedberg, M LeBlanc, M Czuczman, M Kaminski, R Braziel, D Maloney, B Cheson, TP Miller, RI Fisher. American Society of Hematology oral presentation, 2011; <u>Blood</u> 118:abstract 98, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/98?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=S0016&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	3/1/01	9/15/08
S0350	Phase II trial of cisplatin plus etoposide plus Gemcitabine plus solumedrol (PEGS) in Peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). D Mahadevan, JM Unger, DO Persky, C Spier, F Young, M LeBlanc, RI Fisher, TP Miller. 11th International Conference on Malignant Lymphoma (June 15-18, 2011, Lugano, Switzerland), oral presentation.	9/15/05	9/21/10
S9704	Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP±R x 8 vs. CHOP±R x 6 followed by high dose therapy and autotransplant for patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) in the high-intermediate (H-Int) or high IPI risk groups. PJ Stiff, JM Unger, JR Cook, LS Constine, S Couban, T Shea, JN Winter, TP Miller, RR Tubbs, DC Marcellus, JW Friedberg, K Barton, G Mills, M LeBlanc, L Rimsza, SJ Forman, RI Fisher. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), oral presentation, <u>Journal of Clinical Oncology</u> 29:(suppl; abstr 8001), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77208	9/15/97	12/15/07
BMT/CTN 0401	Randomized phase III trial of ¹³¹ iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). JM Vose, SL Carter, LJ Buirns, E Ayala, OW Press, CH Moskowitz, EA Stadtmauer, S Mineishi, RF Ambinder, TS Fenske, MM Horowitz, M Tomblyn. American Society of Hematology annual meeting, oral presentation, 2011; <u>Blood</u> 118:abstract 661, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/661?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=vose&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	2/15/07	7/17/09

E2496	Patterns of failure in patients with stage I/II bulky mediastinal Hodgkin lymphoma (HL) treated with ABVD + Radiotherapy or the Stanford V regimen in the randomized phase III North American Intergroup trial: E2496. RH Advani, F Hong, LI Gordon, RD Gascoyne, H Wagner, RT Hoppe, RI Fisher, L Bartlett, JM Connors, BS Kahl, PJ Stiff, BD Cheson, MK Gospodarowicz, JW Friedberg, KA Blum, TM Habermann, JM Tuscano, SJ Horning. American Society of Hematology, poster presentation. <i>Blood</i> 118(21):abstract 1603, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/1603?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=advani&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	6/15/99	6/15/06
E2496	A gene expression signature in diagnostic formalin fixed paraffin embedded tissue predicts overall survival in locally advanced and advanced stage classical hodgkins lymphoma – a correlative study from the E2496 intergroup trial. DW Scott, FC Chan, F Hong, S Roic, K Tan, B Meissner, P Farinha, SJ Horning, RI Fisher, NL Bartlett, LE Shepherd, JM Connors, AB deSousa, BS Kahl, LI Gordon, C Steidl, RD Gascoyne. American Society of Hematology, oral presentation; <i>Blood</i> 118(21):abstract 430, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/430?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=E2496&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	6/15/99	6/15/06
E4494	Gene expression profiling using paraffin-embedded tissues and the nuclease protection assay in diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: An ECOG and SWOG correlative study of E4494. JN Winter, F Hong, LM Rimsza, ML LeBlanc, D Variakojis, M Krajewska, TM Haberman, AM Melnick, JK Weick, JC Reed, RI Fisher, BS Kahl, RD Gascoyne. 11th International Conference on Malignant Lymphoma (June 15-18, 2011, Lugano, Switzerland), poster presentation.	11/15/99	7/12/01
E4494	Gene risk scores based on expression of 6 genes quantitated by nuclease protein assay in formalin fixed paraffin-embedded DLBCL specimens from CHOP and RCHOP treated patients predicts outcome: an ECOG and SWOG study. JN Winter, Hong F, m LeBlanc, D Variakojis, M Krajewska, TM Habermann, AM Melnick, JW Weick, F Pollock, I Botros, JC Reed, RI Fisher, BS Kahl, RD Gascoyne. American Society of Hematology, oral presentation; . <i>Blood</i> 118(21): abstract 87, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/87?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=SWOG&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/15/99	7/12/01

**SWOG
PUBLICATIONS LIST
LYMPHOMA COMMITTEE 2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED/PRESENTED (2010)			
S8809 S9800 S9911	Prognostic value of regulatory T-cells, lymphoma associated macro-phages and Mum-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group study. JW Sweetenham, B Goldman, M LeBlanc, JR Cook, RR Tubbs, OW Press, DG Maloney, RI Fisher, LM Rimsza, ED Hsi. <u>Annals of Oncology</u> 21(6):1196-1202, 2010. PMC2875547; PMID19875761 http://www.ncbi.nlm.nih.gov/pubmed/19875761	10/1/88 2/5/98 5/15/99	11/15/94 11/15/98 6/1/00
S8819	Tumor-associated macrophages predict long-term survival in classical Hodgkin lymphoma. C Steidl, T Lee, S Shah, P Farinha, G Han, T Nanya, A Delaney, S Jones, M Bast, J Iqbal, A Rosenwald, L Rimsza, E Campo, ES Jaffe, G Lenz, JM Connors, LM Staudt, WC Chan, RD Gascoyne. <u>New England Journal of Medicine</u> , 362(10):875-885, 2010. PMC2897174; PMID20220182 http://www.ncbi.nlm.nih.gov/pubmed/20220182	2/15/89	open
S8819	Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. RD Davis, VN Ngo, G Lenz, P Tolar, RM Young, PB Romesser, H Kohlhammer, L Lamy, H Zhao, Y Yang, W Xu, A Shaffer, G Wright, W Xiao, J Powell, JK Jiang, CJ Thomas, A Rosenwald, G Ott, HK Muller-Hermelink, RD Gascoyne, JM Connors, NA Johnson, LM Rimsza, E Campo, ES Jaffe, WH Wilson, J Delabie, EB Smeland, RI Fisher, RM Braziel, RR Tubbs, JR Cook, DD Weisenburger, WC Chan, SK Pierce, LM Staudt. <u>Nature</u> 463(7277):88-92, 2010. PMC2845535; PMID20054396 http://www.ncbi.nlm.nih.gov/pubmed/20054396	2/15/89	open
S8819	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. E Hartmann, E Campo, G Wright, G Lenz, I Salaverria, P Jares, W Xiao, R Braziel, L Rimsza, W-C Chan, T Weisenburger, J Delabie, E Jaffe, R Gascoyne, S Dave, H-K Mueller-Hermelink, LM Staudt, G Ott, S Bea, A Rosenwald. <u>Blood</u> 116(6):953-961, 2010. PMC2924229; PMID20421449 http://www.ncbi.nlm.nih.gov/pubmed/20421449	02/15/89	open
S8819	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center study. RB Walter, HM Kantarjian, X Huang, SA Pierce, Z Sun, H Gundacker, F Ravandi, S Faderl, M Tallman, F Appelbaum. <u>Journal of Clinical Oncology</u> 28(10):1766-1771, 2010. PMC2849766; PMID:20159819 http://www.ncbi.nlm.nih.gov/pubmed/20159819	02/15/89	open

E4494	Expression of p21 protein predicts clinical outcome in CLBCL patients treated with R-CHOP but not CHOP: a prospective ECOG and SWOG correlative study of E4494. JN Winter, S Li, V Aurora, D Variakojis, B Nelson, M Krajewskia, L Zhang, TM Habermann, RI Fisher, WR Macon, M Chhanabhai, RE Felgar, ED His, LJ Medeiros, JK Weick, EA Weller, A Melnick, JC Reed, SJ Horning, RD Gascoyne. <u>Clinical Cancer Research</u> 16(8):2435-2442, 2010. PMC2865202; PMID20371683 http://www.ncbi.nlm.nih.gov/pubmed/20371683	11/15/99	7/12/01
-------	---	----------	---------

E4494	Comparison of conventional prognostic indices in patients Older than 60 years with diffuse large B-cell lymphoma Treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). RH Advani, H Chen, TM Habermann, V Morrison, E Weller, RI Fisher, BA Peterson, RD Gascoyne, S Horning. <u>British Journal of Haematology</u> 151(2):143-151, 2010. PMID20735398 http://www.ncbi.nlm.nih.gov/pubmed/20735398	11/15/99	7/12/01
-------	--	----------	---------

LYMPHOMA ABSTRACTS PUBLISHED PRESENTED (2010)

*S0433	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group protocol S0433. J Friedberg, J Unger, W Richard Burack, AK Gopal, M LeBlanc, O Press, TP Miller, RI Fisher. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#590, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/590?maxtoshow=&hits=10&RESULTFOR MAT=&fulltext=friedberg&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	11/01/05	3/01/10
*S0515	Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group study S0515. A Stopeck, J Unger, L Rimsza, B Farnsworth, M LeBlanc, M Iannone, RI Fisher, TP Miller. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#591, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/591?maxtoshow=&hits=10&RESULTFOR MAT=&fulltext=stopeck&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	06/15/05	09/15/08
*S8819	Genetic polymorphisms in oxidative stress-related genes correlated with outcome following anthracycline-based therapy for aggressive B-cell non-Hodgkins lymphomas. H Tardif, S Yao, B Goldman, C Spier, M LeBlanc, L Rimsza, D Persky, T Miller, RI Fisher, C Ambrosone, M Briehl. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#321, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/321?maxtoshow=&hits=10&RESULTFOR MAT=&fulltext=tardif&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	02/15/89	open

S9704	Diffuse large B-cell lymphomas with high grade morphologic features and/or MYC translocations lack distinctive clinicopathologic features at presentation: a SWOG S9704 study. J Cook, R Tubbs, L Rimsza, P Stiff, M LeBlanc, R Fisher, B Goldman. Poster presentation, United States and Canadian Academy of Pathology's 99 th Annual Meeting (March 20-26, 2010, Washington, DC), abstr 1308. http://www.abstracts2view.com/uscap10/view.php?nu=USCAP10L_1308&terms=	9/15/97	12/15/07
*E2496	A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). L Gordon, F Hong, RI Fisher, N Bartlett, JM Connors, R Gascoyne, H Wagner, P Stiff, B Cheson, M Gospodarowicz, R Advani, B Kahl, J Friedberg, K Blum, T Habermann, J Tuscano, R Hoppe, R Horning. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#415, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/415?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=gordon&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	06/15/99	06/15/06
*E4494/C9793	R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of Intergroup E4494/C9793. V Morrison, F Hong, T Haberman, RI Fisher, B Cheson, B Kahl, SJ Horning, B Peterson. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#589, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/589?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=morrison&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	11/15/99	07/12/01

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
LYMPHOMA COMMITTEE 2009**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LYMPHOMA MANUSCRIPTS PUBLISHED/PRESENTED (2009)			
S0108	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-hodgkins lymphoma: Southwest Oncology Group study S0108. A Stopeck, J Unger, LM Rimsza, WT Bellamy, M Iannone, DO Persky, M Leblanc, RI Fisher, TP Miller. <u>Leukemia and Lymphoma</u> 50(5):728-735, 2009. PMC2845535; PMID: 19373598	4/15/01	12/01/04
S8516	The natural history of central nervous system (CNS) relapse in patients with aggressive non-hodgkin's lymphoma: a 20 year follow-up analysis of Southwest Oncology Group (SWOG) 8516. SH Bernstein, JM Unger, M LeBlanc, J Friedberg, TP Miller, RI Fisher. <u>Journal of Clinical Oncology</u> , 27(1):114-119, 2009. PMID: 19047289	4/4/86	6/15/91
S8819	Follicular lymphomas with and without translocation t(14:18) differ in gene expression profiles and genetic alterations. E Leich, I Salaverria, S Bea, A Zettl, G Wright, V Moreno, R Gascoyne, R Braziel, L Rimsza, D Weisenburger, J Delabie, E Jaffe, A Liser, J Fitzgibbon, L Staudt, E Hartmann, H Mueller-Hermelin, E Campo, G Ott, A Rosenwald. <u>Blood</u> 114:826-834, 2009. PMC2716022; PMID: 19471018	2/15/89	open
S8819	Array-based DNA methylation profiling in follicular lymphoma. C O'Riain, DM O'Shea, Y Yang, R LeDieu, JF Gribben, K Summers, J Yeboah-Afari, L Bhaw-Rosu, C Fleischmann, CA Mein, T Crook, P Smith, G Kelly, A Rosenwald, G Ott, E Campo, L Rimsza, EB Smeland, WC Chan, N Johnson, R Gascoyne, S Reimer, R Braziel, WG Wright, LM Staudt, TA Lister, J Fitzgibbon. <u>Leukemia</u> 23(10):1858-1866, 2009. PMC2762475; PMID: 19587707	2/15/89	open
S8819	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. A Mozos, C Royo, E Hartman, D DeJong, C Baro, A Valera, K Fu, D Weisenburger, J Delabie, SS Chuang, ES Jaffe, C Ruiz-Marcellan, S Dave, L Rimsza, R Braziel, R Gascoyne, F Sole, A Lopez-Guillermo, D Colomer, LM Staudt, A Rosenwald, G Ott, P Jares, E Campo. <u>Haematologica</u> 94(11):1555-1562, 2009. PMC2770966; PMID: 19880778	2/15/89	open

LYMPHOMA PUBLISHED/PRESENTED ABSTRACTS (2009)

S8809	Fc gamma receptor 3a genotype predicts overall	10/1/88	11/15/94
S9800	survival for follicular lymphoma patients treated on	2/5/98	11/15/98
S9911	Southwest Oncology Group trials with combined mono- clonal antibody plus chemotherapy but not chemotherapy alone. D Persky, D Bornan, B Goldman, M LeBlanc, RM Braziel, RI Fisher, D Maloney, T Miller, OW Press, LM Rimsza. Blood 114:abst. #111, 2009 (ASH Annual Meeting, oral presentation)	5/15/99	6/1/00
S8819	MYC translocations and expression are clinically Important in R-CHOP treated patients with de novo DLBCL. NA Johnson, S Ben-Neriah, KJ Savage, T Lee, DE Horsman, JM Connors, WC Chan, G Lenz, G Wright, L Rimsza, R Braziel, J Cook, R Tubbs, D Weisenburger, E Campo, A Rosenwald, G Ott, J Delabie, ES Jaffe, LM Staudt, RD Gascoyne. Blood 114:abst. #1100, 2009 (ASH Annual Meeting, poster)	2/15/89	open
S8819	High microvascular density correlates independently with poor outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus chemotherapy (R-CT). T Cardesa, L Colomo, F Climent, E Gonzalez-Barca, G Gutierrez, S Mercadal, RD Gascoyne, J Connors, L Rimsza, R Braziel, J Cook, R Tubbs, A Rosenwald, G Ott, JL Mate, JM Ribera, L Arenillas, S Serrano, N Combalia, J Delabie, G Lenz, G Wright, E Jaffe, L Staudt, WC Chan, D Weissenburger, A Lopez-Guillermo, E Campo. Blood 114:abst. #1948, 2009 (ASH Annual Meeting, poster)	2/15/89	open
S8819	Chromosomal alterations in gene expression-defined pediatric aggressive B-cell non-hodgkin lymphomas (B-NHL). D Deffenbacher, J Iqbal, Z Liu, S Perkins, M Lim, K Fu, J Shen, L Staudt, L Rimsza, E Jaffe, A Rosenwald, J Delabie, J Campo, R Gascoyne, D Weisenberger, T Greiner, TG Gross, W Chan. Blood 114:abst.#2922, 2009 (ASH Annual Meeting, poster presentation).	2/15/89	open
*S8819	Accurate classification of diffuse large b cell lymphoma into germinal center and activated b cell subtypes using a nuclease protection assay on formalin fixed paraffin embedded: a study from the lymphoma and Leukemia Molecular Profiling Project. LM Rimsza, GL Wright, M Schwartz, J Chan, E Jaffe, R Gascoyne, E Campo, A Rosenwald, G Ott, J Cook, RR Tubbs, R Braziel, J Delabie, T Miller, RI Fisher, L Staudt. Blood 114:abst.#620, 2009 (ASH, oral presentation)	2/15/89	open

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2008**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
S8819/9800 (2570)	Stromal gene signatures in large-B-cell lymphomas. G Lenz, G Wright, S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal, J Vose, M Bast, K Fu, D Weisenburger, T Greiner, J Armitage, A Kyle, L May, R Gascoyne, J Connors, G Troen, H Holte, S Kvaloy, D Dierickx, IG Verhoef, J Delabie, E Smeland, P Jares, A Martinez, A Lopez-Guilldermo, E Montserrat, E Campo, R Braziel, T Miller, L Rimsza, J Cook, B Pohlman, J Sweetenham, R Tubbs, R Fisher, E Hartmann, A Rosenwald, G Ott, HK Muller-Hermelink, D Wrench, T Lister, E Jaffe, W Wilson, W Chang, L Staudt. <u>NewEngland Journal of Medicine</u> , 359(22):22313-2323, 2008. PMID: 19038878	Lymph	2/15/89 2/15/98	open 11/15/98
9239 (2474)	Prospective study of sequential reduction in immuno-suppression, interferon alpha-2B, and chemotherapy for post-transplantation lymphoproliferative disorders (PTLD). LJ Swinnen, M. LeBlanc, TM Grogan, LI Gordon, PJ Stiff, AM Miller, Y Kasamon, TP Miller, RI Fisher. <u>Transplantation</u> 86(2):215-222, 2008. PMID: 18645482	Lymph	8/15/00	8/15/01
9438 (2430)	Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: Results of a Phase III randomized trial by the Southwest Oncology Group (SWOG 9438). JA Thompson, RI Fisher, M LeBlanc, SJ Forman, OW Press, JM Unger, AP Nademanee, PJ Stiff, SH Petersdorf, A Fefer. <u>Blood</u> 111(80):4048-4054, 2008. PMID: 18256325	Lymph	5/15/95	7/1/04
S0014 (2405)	Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with early-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. DO Persky, JM Unger, CM Spier, B Stea, M LeBlanc, MJ McCarty, LM Rimsza, RI Fisher, TP Miller. <u>Journal of Clinical Oncology</u> 26(14):2258-2263, 2008. PMID: 18413640	Lymph	4/1/00	1/15/02
Multiple (2578)	Oncogenic CARD11 mutations in human diffuse large B cell Lymphoma. G Lenz, ER davis, VN Ngo, L Lam, TC George, GW Wright, SS Dave, H Zhao, W Xu, A Rosenwald, G Ott, HK Muller-Hermelink, RD Gascoyne, JM Connors, LM Rimsza, Elias Campo, ES Jaffe, J Delabie, EB Smeland, RI Fisher, WC Chan, LM Staudt for the Leukemia Lymphoma Molecular Profiling Project. <u>Science</u> 319:1676-1679, 2008. PMID: 183233416	Lymph	n/a	n/a

Multiple (2569)	Molecular subtypes of diffuse large cell b cell lymphoma arise by distinct genetic pathways. G Lenz, GW Wright, T Emre, H Kohlhammer, SS Dave, ER Davis S Carty, LT Lam, AL Shaffer, W Xiao, J Powell, A Rosenwald, Ott, HK Muller-Hermelink, RD Gascoyne, JM Connors, E Campo, ES Jaffe, J Delabie, EB Smeland, LM Rimsza, J Fisher, DD Weisenburger, WC Chan, LM Staudt. <u>Proceedings of the National Academy of Sciences</u> , 105(36):13520-13525, 2008. PMID: 18765795	Lymph	n/a	n/a
None (2573)	Non-hodgkins lymphoma. R Fisher, P Mauch, J Friedberg, L Rimsza. In Cancer: Principles and Practice of Oncology, 8 th edition, DeVita VT, Hellman S, Rosenberg SA, eds., Lippincott, Williams & Wilkins, Baltimore, MD. pp. 2098-2158, 2008.	Lymph	n/a	n/a

ABSTRACTS PUBLISHED/PRESENTED

*S8809 S9800 S9911 (2590)	MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immuno-chemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study. ED Hsi, B Goldman, LM Rimsza, JR Cook, RR Tubbs, OW Press, DG Maloney, RI Fisher, JW Sweetenham. 2008 Annual Meeting of the American Society of Hematology (December). <u>Blood</u> 112(11):146, abst. #376. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/376?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=hsi&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Lymph	10/1/88 2/15/98 5/15/99	11/15/94 11/15/98 6/1/2000
S8819 (2619)	Genetic abnormalities involved in the development and progression of follicular lymphoma. KE Deffenbacher, G Wright, J Iqbal, H Geng, D O'Shea, TA Lister, J Fitzgibbon, K Fu, Z Liu, D Weisenburger, TC Greiner, RD Gascoyne, A Rosenwald, E Campo, LM Rimsza, J Delabie, ES Jaffe, LM Staudt, WC Chan. 2008 Annual Meeting of American Society of Hematology (December). <u>Blood</u> 112(11): abst.#2049, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/2049?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=deffenbacher+ke&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Lymph	2/15/89	OPEN
*S8819 (2617)	Molecular signatures implicate innate immune cells, fibrosis, and angiogenesis in survival following CHOP treatment of diffuse large B cell lymphoma. G Lenz, G Wright, SS Dave, W Xiao, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal, J Vose, M Bast, K Fu, DD Weisenburger, TC Greiner, JO Armitage, A Kyle, L May, RD Gascoyne, JM Connors, G Troen, H Holte, S Kvaloy, D Dierickx, G Verhoef, J Delabie, EB Smeland, P Jares, A Martinez, A Lopez-Guillermo, E Montserrat, E Campo, RM Braziel, TP Miller, LM Rimsza, JR Cook, B Pohlman, J Sweetenham, RR Tubbs, RI Fisher, E Hartmann, A Rosenwald, G Ott, HK Muller-Hermelink, D Wrench, TA Lister, ES Jaffe, WH Wilson, WC Chan, LM Staudt. 2008 Annual Meeting of American Society of Hematology (December). <u>Blood</u> 112(11):181, abst.#475, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/475?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=lenz&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Lymph	2/15/89	OPEN

S0016	Effect of rituximab on residence time of I-131 tositumomab	Lymph	3/1/01	
S0433/ (2602)	consolidation therapy in patients (pts) with non-Hodgkin's lymphoma (NHL): analysis of SWOG clinical trials. J Schaefer-Cuttillo, V Chengazi, D Peterson, D Maloney, K Kibler, E Cebula, S Bernstein, F Young, O Press, L Rimsza, R Fisher, J Friedberg. 2008 Annual Meeting of American Society of Hematology (December). <u>Blood</u> 112(11):697-698, abst.#2000, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/2000?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=schaefer-cuttillo&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	9/15/08 Lymph	11/1/05	n/a
S0313 (2604)	Effect of adding ibritumomab tiuxetan (Zevalin) radio-immunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive diffuse B-cell lymphoma (Southwest Oncology Group Study 0313). TP Miller, JM Unger, CM Spier, B Stea, O Press, M LeBlanc, RI Fisher. 2008 Annual Meeting of American Society of Hematology (December). <u>Blood</u> 112(11):1231, abst. #3598, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/3598?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=unger&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Lymph	2/1/04	n/a
*Multiple (2618)	Genome-wide expression profiling predicts treatment outcome in classical hodgkins lymphoma. C Steidl, T Lee, S Shah, G Han, T Nayar, A Delaney, S Jones, WC Chan, A Rosenwald, LM Rimsza, E Campo, ES Jaffe, LM Staudt, G Lenz, JM Connors, RD Gascoyne. 2008 Annual Meeting of American Society of Hematology (December). <u>Blood</u> 112(11): abst. #520, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/520?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=steidl&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Lymph	n/a	n/a

*oral presentation

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8819 (2394)	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. G Lenz, I Nagel, R Siebert, AV Roschke, W Sanger, GW Wright, SS Dave, B Tan, H Zhao, A Rosenwald, HK Muller-Hermelink, RD Gascoyne, E Campo, ES Jaffe, EB Smeland, RI Fisher, WM Kuehl, WC Chan, LM Staudt. <u>Journal of Experimental Medicine</u> 204:633-643, 2007.	Lymphoma	02/15/89	
8819 (2410)	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. A Wiestner, M Tehrani, M Chiorazzi, G Wright, F Gibellini, K Nakayama, H Liu, A Rosenwald, HK Muller-Hermelink, G Ott, WC Chan, TC Greiner, DD Weisenburger, J Vose, JO Armitage, RD Gascoyne, JM Connors, E Campo, E Montserrat, F Bosch, EB Smeland, S Kvaloy, H Holte, J Delabie, RI Fisher, TM Grogan, TP Miller, WH Wilson, EJ Jaffe, LM Staudt, for the Lymphoma/Leukemia Molecular Profiling Project. <u>Blood</u> 109(11):4599-4606, 2007.	Lymph	2/15/89	
8819 (2459)	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. LR Kimm, RJ deLeeuw, KJ Savage, A Rosenwald, E Campo, J Delabie, G Ott, HK Muller-Hermelink, ES Jaffe, LM Rimsza, DD Weisenburger, WC Chan, LM Staudt, JM Connors, RD Gascoyne, WL Lam. <u>Genes, Chromosomes & Cancer</u> 46:1080-1097, 2007.	Lymphoma	2/15/89	
8819	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. J Iqbal, TC Greiner, K Patel, BJ Dave, L Smith, J Ji, G Wright, WG Sanger, DL Pickering, S Jain, DE Horsman, Y Shen, K Fu, DD Weisenburger, CP Hans, E Campo, RD Gascoyne, A Rosenwald, ES Jaffe, J Delabie, L Rimsza, G Ott, HK Muller-Hermelink, JM Connors, JM Vose, T McKeithan, LM Staudt, WC Chan. <u>Leukemia</u> 21(11):2332-2343, 2007. PMID: 17625604	Lymphoma	2/15/89	
8819	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. KH Young, DD Weisenburger, B Dave, L Smith, W Sanger, E Campo, J Delabie, RD Gascoyne, LM Rimsza, HK Müller-Hermelink, ES Jaffe, A Rosenwald, LM Staudt, WC Chan, TC Greiner. <u>Blood</u> 110(13):4396-4405, 2007. PMID: 17881637	Lymphoma	2/15/89	

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (2411)	Revised response criteria for malignant lymphoma. BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, B Coiffier, RI Fisher, A Hagenbeck, E Zucca, ST Rosen, S Stroobants, TA Lister, RT Hoppe, M Dreyling, K Tobinai, JM Vose, JM Connors, M Federico, V Diehl. <u>Journal of Clinical Oncology</u> 25(5):579-586, 2007.	Lymph		
None	Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. J Schaefer-Cuttillo, JW Friedberg, RI Fisher. <u>Oncology</u> 21(2):203-212, 2007. PMID: 17396483	Lymph	n/a	n/a
ABSTRACTS PUBLISHED/PRESENTED				
*8516 (2419)	Central nervous system (CNS) relapse in aggressive non-Hodgkin's lymphoma; does CNS prophylaxis work? SH Bernstein, J Unger, M LeBlanc, RI Fisher. <u>Blood</u> 110(11):#520, 2007.	Lymph	4/4/86	6/15/91
*8809/S9911 (2413)	Numbers of lymphoma associated macrophages (LAMS) and regulatory T-cells (Tregs) in follicular lymphoma (FL) patients (pts) treated with and without monoclonal antibody (MoAb)-containing therapy do not correlate with overall survival (OS): a study from the Southwest Oncology Group (SWOG). JW Sweetenham, E Hsi, B Goldman, M LeBlanc, RR Tubbs, JR Cook, OW Press, RI Fisher, LM Rimsza. <u>Blood</u> 110(11):#2602, 2007.	Lymph		
8819	Distinct genetic aberrations in molecular subtypes of diffuse large B cell lymphoma detected by array CGH. G Lenz, GW Wright, S Dave, W Xiao, J Powell, A Rosenwald, H-K Muller-Hermelink, RD Gascoyne, JM Connors, E Campo, ES Jaffe, J Delabie, EB Smeland, L Rimsza, RI Fisher, WC Chan, LM Staudt. <u>Blood</u> 110(11):#2631, 2007.	Lymphoma	2/15/89	
8819	Gene expression model of survival and transformation in follicular lymphoma (FL): a study by the LLMP. NA Johnson, T Nayar, SS Dave, G Wright, A Rosenwald, WC Chan, M Bast, LM Rimsza, H Holte, J Delabie, JM Connors, A Al-Tourah, L Colomo, E Campo, TA Lister, D O'Shea, LM Staudt, RD Gascoyne. <u>Blood</u> 110(11):#2606, 2007	Lymphoma	2/15/89	
*8819	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. E Leich, I Salaverria, S Bea, A Zettl, RD Gascoyne, W-C Chan, RM Braziel, LM Rimsza, DD Weisenburger, J Delabie, ES Jaffe, TA Lister, AJ Norton, LM Staudt, EM Hartmann, H-K Mueller-Hermelink, E Campo, G Ott, A Rosenwald. <u>Blood</u> 110(11):#360, 2007.	Lymphoma	2/15/89	
*S0213 (2412)	A multi center trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma. EM Epner, J Unger, T Miller, L Rimsza, C Spier, M LeBlanc, R Fisher. <u>Blood</u> 110(11):#387, 2007.	Lymph	10/1/02	9/1/06

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S0517 (2415)	Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. MK Kirschbaum, BH Goldman, JM Zain, JR Cook, LM Rimsza, SJ Forman, RI Fisher. <u>Blood</u> 110(11):#2574, 2007.	Lymph	9/15/05	8/1/07

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
S9911 (2270)	Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911. OW Press, JM Unger, RM Brazier, DG Maloney, TP Miller, M LeBlanc, RI Fisher. <u>Journal of Clinical Oncology</u> 24(25): 4143-4149, 2006.	Lymph	5/15/99	6/1/00
E4494 (2282)	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. JN Winter, EA Weller, SJ Horning, M Krajewska, D Variakojis, TM Habermann, RI Fisher, PJ Kurtin, WR Macon, M Chhanabhai, RE Felgar, ED His, LJ Medeiros, JK Weick, JC Reed, RD Gascoyne. <u>Blood</u> 107(11):4207-4213, 2006.	Lymph	11/15/99	7/12/01
E4494 (2278)	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. TM Habermann, EA Weller, VA Morrison, RD Gascoyne, PA Cassileth, JB Cohn, SR Dakhil, B Woda, RI Fisher, BA Peterson, SJ Horning. <u>Journal of Clinical Oncology</u> , 24(19):3121-3127, 2006.	Lymph	11/15/99	7/12/01
Multiple Studies (2283)	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. LM Rimsza, RA Roberts, E Campo, TM Grogan, S Bea I Salaverria, A Zettl, A Rosenwald, G Ott, HK Muller-Hermelink, J Delabie, RI Fisher, JM Unger, M LeBlanc, LM Staudt, ES Jaffe, RD Gascoyne, WC Chan, DD Weisenburger, T Greiner, RM Brazier, TP Miller. <u>Blood</u> 107(3):1101-1107, 2006.	Lymph		
Multiple Studies (2288)	Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. RA Roberts, G Wright, AR Rosenwald, MA Jaramillo, TM Grogan, TP Miller, Y Frutiger, WC Chan, RD Gascoyne, G Ott, HK Muller-Hermelink, LM Staudt, LM Rimsza. <u>Blood</u> 108(1):311-318, 2006.	Lymph		
Multiple Studies (2304)	Molecular diagnosis of Burkitt's lymphoma. SS Dave, K Fu, GW Wright, LT Lam, P Kluin, EJ Boerma, TC Greiner, DD Weisenburger, A Rosenwald, G Ott, HK Muller-Hermelink, RD Gascoyne, J Delabie, LM Rimsza, RM Brazier, TM Grogan, E Campo, ES Jaffe, BJ Dave, W Sanger, M Bast, JM Vose, JO Armitage, JM Connors, EB Smeland, S Kvaloy, H Holte, RI Fisher, TP Miller, E Montserrat, WH Wilson, M Bahl, H Zhao, L Yang, J Powell, R Simon, WC Chan, LM Staudt. <u>New England Journal of Medicine</u> 354(23): 2431-2442, 2006.	Lymph		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (2284)	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. TC Greiner, C Dasgupta, VV Ho, DD Weisenburger, LM Smith, JC Lynch, JM Vose, K Fu, JO Armitage, RM Braziel, E Campo, J Delabie, RD Gascoyne, ES Jaffe, HK Muller-Hermelink, G Ott, A Rosenwald, LM Staudt, MY Im, MW Karaman, BL Pike, WC Chan, JG Hacia. <u>Proc of the National Academy of Sciences</u> 103(7):2352-2357, 2006.	Lymph		
Multiple Studies (2390)	Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. CF Haare, RA Roberts, YM Frutiger, TM Grogan, LM Rimsza. <u>Archives of Pathology & Laboratory Medicine</u> 130:1819-1824, 2006.	Lymph		
Multiple Studies (2418)	Diffuse aggressive histologies of non-Hodgkin lymphoma: treatment and biology of limited disease. TP Miller, CM Spier, L Rimsza. <u>Seminars in Hematology</u> 43: 207-212, 2006.	Lymph		

ABSTRACTS PUBLISHED/PRESENTED

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

Multiple Studies (2279)	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. S Bea, A Zettl, G Wright, I Salaverria, P Jehn, V Moreno, C Burek, G Ott, X Puig, L Yang, A Lopez-Guillermo, WC Chan, TC Greiner, DD Weisenburger, JO Armitage, RD Gascoyne, JM Connors, TM Grogan, R Braziel, RI Fisher, EB Smeland, S Kvaloy, H Holte, J Delabie, R Simon, J Powell, WH Wilson, ES Jaffe, E Montserrat, HK Muller-Hermelink, LM Staudt, E Campo, A Rosenwald. <u>Blood</u> 106(9):3183-3190, 2005.	Lymph		
Multiple Studies (2273)	Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. RI Fisher. <u>Journal of Clinical Oncology</u> 23(4):657-658, 2005.	Lymph		
Multiple Studies (2253)	Meta-analysis to evaluate the role of interferon in follicular lymphoma. AZS Rohatiner, WM Gregory, B Peterson, E Borden, P Solal-Celigny, A Hagenbeek, RI Fisher, M Unterhalt, R Arranz, T Chisesi, A Aviles, TA Lister. <u>Journal of Clinical Oncology</u> 23(10):2215-2223, 2005.	Lymph		
Multiple Studies (2219)	New treatment options have changed the survival of patients with follicular lymphoma. RI Fisher, M LeBlanc, OW Press, DG Maloney, JM Unger, TP Miller. <u>Journal of Clinical Oncology</u> 23(33):8447-8452, 2005.	Lymph		
Multiple Studies (2287)	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. D Mahadevan, C Spier, K Della Croce, S Miller, B George, C Riley, S Warner, TM Grogan, TP Miller. <u>Molecular Cancer Therapeutics</u> 4(12):1867-1879, 2005.	Lymph		

ABSTRACTS PUBLISHED/PRESENTED

8819 (2292)	Gene Expression Distinguishes Burkitt Lymphoma from Other Aggressive Lymphomas and Identifies Patients Who Are Highly Curable with Intensive Chemotherapeutic Regimens. SS Dave, K Fu, G Wright, L Lam, TC Greiner, DD Weisenburger, PM Klein, E Boerma, A Rosenwald, G Ott, HK Muller-Hermelink, RD Gascoyne, J Delabie, LM Rimsza, RM Braziel, TM Grogan, E Campo, ES Jaffe, J Vose, JO Armitage, JM Connors, EB Smeland, S Kvaloy, H Holte, TP Miller, RI Fisher, E Montserrat, WH Wilson, M Bahl, H Zhao, L Yang, J Powell, R Simon, WC Chan, LM Staudt. <u>Blood</u> 106(11): #415, 2005.	Lymph	2/15/89	Open
----------------	--	-------	---------	------

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9911 (2213)	An update of a phase II trial of CHOP followed by tositumomab/iodine I-131 tositumomab (Bexxar) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911. OW Press, J Unger, D Maloney, RM Brazier, M LeBlanc, T Grogan, TP Miller, RI Fisher. Blood (ASH Annual Meeting Abstracts) 106(11): #352, 2005.	Lymph	5/15/99	6/1/00
*S0108 (2158)	Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108. AT Stopeck, W Bellamy, J Unger, L Rimsza, M Iannone, RI Fisher, TP Miller. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):583s (#6592), 2005.	Lymph	4/15/01	12/1/04

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8809 (2117)	Follicular lymphoma international prognostic index. P Solal-Celigny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, WY Au, M Bellei, P Brice, D Caballero, B Coiffier, E Conde-Garcia, C Doyen, M Federico, RI Fisher, JF Garcia-Conde, C Guglielmi, A Hagenbeek, C Haioun, M LeBlanc, AT Lister, A Lopez-Guillermo, P McLaughlin, N Milpied, P Morel, N Mounier, SJ Proctor, A Rohatiner, P Smith, P Soubeyran, H Tilly, U Vitolo, PL Zinzani, E Zucca, E Montserrat. <u>Blood</u> 104(5):1258- 1265, 2004.	Lymph	10/1/88	11/15/94
8819 (2122)	Allelic loss during progression of follicular lymphoma. S Takeuchi, S de Vos, N Takeuchi, AC Fermin, TM Grogan, H Seo, JW Said, HP Koeffler. <u>Leukemia Research</u> 28:567-569, 2004.	Lymph	2/15/89	OPEN
8819 (2019)	Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the leukemia and lymphoma molecular profiling project. L Rimsza, RA Roberts, TP Miller, JM Unger, M LeBlanc, R Braziel, DD Weisenburger, WC Chan, K Muller-Hermelink, Es Jaffe, RD Gascoyne, E Campo, D Fuchs, CM Spier, RI Fisher, J Delabie, A Rosenwald, LM Staudt, T Grogan. <u>Blood</u> 103(11):4251-4258, 2004.	Lymph	2/15/89	OPEN
8819 (2119)	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. SS Dave, G Wright, B Tan, A Rosenwald, RD Gascoyne, WC Chan, RI Fisher, RM Braziel, LM Rimsza, TM Grogan, TP Miller, M LeBlanc, TC Greiner, DD Weisenburger, JC Lynch, J Vose, JO Armitage, EB Smeland, S Kvaloy, H Holte, J Delabie, JM Connors, P Lansdorp, Q Ouyang, TA Lister, AJ Davies, AJ Norton, HK Muller-Hermelink, G Ott, E Campo, E Montserrat, WH Wilson, ES Jaffe, R Simon, L Yang, J Powell, H Zhao, N Goldschmidt, M Chiorazzi, LM Staudt. <u>New England Journal of Medicine</u> 351(21):2159-2169, 2004.	Lymph	2/15/89	OPEN
ABSTRACTS PUBLISHED/PRESENTED				
*8736 (2128)	Histologic subtypes do not confer unique outcomes in early-stage lymphoma: long term follow up of SWOG 8736. CM Spier, M LeBlanc, EM Chase, RI Fisher, TP Miller. <u>Blood</u> 104(11): #3263, 2004.	Lymph	3/15/88	6/15/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8819 (2120)	Chromosomal imbalances in germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma influence gene expression signatures and improve gene expression-based survival prediction. A Zettl, S Bea, G Wright, I Salaverria, P Jehn, G Ott, WC Chan, E Jaffe, D Weisenburger, T Greiner, J Armitage, R Gascoyne, J Connors, T Grogan, T Miller, R Fisher, J Delabie, S Kvaloy, HK Mueller-Hermelink, V Moreno, E Montserrat, W Wilson, L Staudt, A Rosenwald, E Campo. <u>Blood</u> 104(11): #415, 2004.	Lymph	2/15/89	OPEN
8819 (2116)	Downregulated antioxidant defense enzyme expression is correlated with poor survival in DLBCL. DB Johnson, ME Tome, LM Rimsza, RA Roberts, W Browne, TM Grogan, TP Miller, MM Briehl. <u>Federation of American Societies for Experimental Biology</u> 18(5):A953 (#626.6), 2004.	Lymph	2/15/89	OPEN
8819 (2131)	Gene expression profiling, frozen and paraffin section immunohistochemistry, and in situ hybridization for determination of monoclonality in diffuse large B-cell lymphoma. MW Andres, RA Roberts, DJ Mustacich, RD Gascoyne, DA Fuchs, MX Wang, RM Brazier, WC Chang, TM Grogan, LM Rimsza. <u>Blood</u> 104(11): #4553, 2004.	Lymph	2/15/89	OPEN
*8819 (2129)	HLA-DR protein status predicts survival in patients with diffuse large B cell lymphoma (DLBCL) treated with the MACOP-B chemotherapy regimen. LM Rimsza, P Farinha, DA Fuchs, H Masoudi, JM Connors, RD Gascoyne. <u>Blood</u> 104(11): #3273, 2004.	Lymph	2/15/89	OPEN
*9208 (2052)	Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) study 9133. PA Ganz, CM Moinpour, S McCoy, DK Pauler, OW Press, RI Fisher. <u>Proc of the American Society of Clinical Oncology</u> 23:567 (#6546), 2004.	Lymph	4/15/94	4/24/00
*9438 (2103)	Impact of increased body weight on acute toxicity and outcome of autologous stem cell transplantation for non-Hodgkin's lymphoma: a Southwest Oncology Group analysis. P Stiff, J Unger, S Forman, M LeBlanc, T Miller, O Press, J Thompson, R Fisher. <u>Blood</u> 104(11): #352, 2004.	Lymph	5/15/95	7/1/04
*S9800 (2130)	FC receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800). DG Maloney, B Pender-Smith, JM Unger, RM Brazier, J Radich, OW Press, TP Miller, TM Grogan, M LeBlanc, RI Fisher. <u>Blood</u> 104(11): #589, 2004.	Lymph	2/15/98	11/15/98
*S0014 (2104)	Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). TP Miller, JM Unger, C Spier, B Stea, E Cantu, M LeBlanc, RI Fisher. <u>Blood</u> 104(11): #158, 2004.	Lymph	4/1/00	1/15/02

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S0108 (2095)	Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's Lymphoma: Correlative studies from the SWOG S0108 trial. A Stopeck, M Iannone, L Rimsza, T Miller, R Fisher, W Bellamy. <u>Blood</u> 104(11): #2288, 2004.	Lymph	4/15/01	OPEN\
*E4494 (2102)	Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. TM Habermann, E Weller, VA Morrison, PA Cassileth, J Cohn, S Dakhil, RD Gascoyne, B Woda, R Fisher, BA Peterson, SJ Horning. <u>Blood</u> 104(11): #127, 2004.	Lymph	11/15/99	7/12/01
*Multiple Studies (2149)	LymphDx: a custom microarray for molecular diagnosis and prognosis in Non-Hodgkin Lymphoma. SS Dave, G Wright, B Tan, A Rosenwald, WC Chan, TC Greiner, DD Weisenburger, JC Lynch, JM Vose, JO Armitage, RI Fisher, RM Braziel, LM Rimsza, TM Grogan, TP Miller, M LeBlanc, EB Smeland, S Kvaloy, H Holte, J Delabie, HK Muller-Hermelink, G Ott, RD Gascoyne, JM Connors, E Campo, E Montserrat, WH Wilson, ES Jaffee, TA Lister, AJ Davies, AJ Norton, R Simon, L Yang, J Powell, J Palma, J Warrington, H Zhao, M Chiorazzi, LM Staudt. <u>Blood</u> 104(11): #701, 2004.	Lymph		
*Multiple Studies (2105)	New treatment options have changed the natural history of follicular lymphoma. RI Fisher, M LeBlanc, OW Press, DG Maloney, TP Miller. <u>Blood</u> 104(11): #583, 2004.	Lymph		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8819 (1864)	Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma(MCL) and MCL-BV. S deVos, U Krug, WK Hofmann, GS Pinkus, SH Swerdlow, W Wachsman, TM Grogan, JW Said, HP Koeffler. <u>Diagnostic Molecular Pathology</u> 12(1):35-43, 2003.	Lymph	2/15/89	OPEN
8819 (1813)	Gene expression profile of serial samples of transformed B-cell lymphomas. S de Vos, WK Hofmann, TM Grogan, U Krug, M Schrage, TP Miller, JG Braun, W Wachsman, HP Koeffler, JW Said. <u>Laboratory Investigation</u> 83(2):271-285, 2003.	Lymph Lymph Bio	2/15/89	OPEN
8819 (2118)	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to hodgkin lymphoma. A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, WC Chan, T Zhao, C Haioun, TC Greiner, DD Weisenburger, JC Lynch, J Vose, JO Armitage, EB Smeland, S Kvaloy, H Holte, J Delabie, E Campo, E Montserrat, A Lopez-Guillermo, G Ott, HK Muller-Hermelink, JM Connors, R Braziel, TM Grogan, RI Fisher, TP Miller, M LeBlanc, M Chiorazzi, H Zhao, L Yang, J Powell, WH Wilson, ES Jaffe, R Simon, RD Klausner, LM Staudt. <u>Journal of Experimental Medicine</u> 198(6):851-862, 2003.	Lymph	2/15/99	OPEN
8819 (2043)	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, RD Gascoyne, TM Grogan, HK Muller-Hermelink, EB Smeland, M Chiorazzi, JM Giltneane, Em Hurt, H Zhao, L Averett, S Henrickson, L Yang, J Powell, WH Wilson, ES Jaffe, R Simon, RD Klausner, E Montserrat, F Bosch, TC Greiner, DD Weisenburger, WG Sanger, BJ Dave, JC Lynch, J Vose, JO Armitage, RI Fisher, TP Miller, M LeBlanc, G Ott, S Kvaloy, H Holte, J Delabie, LM Staudt. <u>Cancer Cell</u> 3:185-197, 2003.	Lymphoma	2/15/89	OPEN
8903/9349 (1843)	Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma. a phase II study of the Southwest Oncology Group (SWOG 9349). DW Blayney, ML LeBlanc, T Grogan, ER Gaynor, RA Chapman, CH Spiridonidis, SA Taylor, SI Bearman, TP Miller, RI Fisher. <u>Journal of Clinical Oncology</u> 21(13):2466-2473, 2003.	Lymphoma	9/15/94	1/15/99
8952 (1900)	Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. DB Duggan, GR Petroni, JL Johnson, JH Glick, RI Fisher, JM Connors, GP Canellos, BA Peterson. <u>Journal of Clinical Oncology</u> 21(4):607-614, 2003.	Lymph	3/1/90	11/10/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9011 (1849)	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. PJ Stiff, JM Unger, SJ Forman, AR McCall, M LeBlanc, AP Nademanee, BJ Bolwell, RI Fisher. <u>Biology of Blood and Marrow Transplantation</u> 9:529-539, 2003.	Lymphoma	4/15/90	12/1/95
9208 (1998)	Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133. PA Ganz, CM Moinpour, DK Pauler, AB Kornblith, ER Gaynor, SP Balcerzak, GS Gatti, HP Erba, S McCoy, OW Press, RI Fisher. <u>Journal of Clinical Oncology</u> 21(18):3512-3519, 2003.	Lymphoma	4/15/94	4/24/00
9239 (1869)	Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. ML Gulley, LJ Swinnen, KT Plaisance Jr, C Schnell, TM Grogan, BG Schneider. <u>Transplantation</u> 76(6):959-964, 2003.	Lymph Lymph Bio	4/15/95	8/15/00
9501 (1848)	Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. WS Velasquez, D Lew, TM Grogan, CH Spiridonidis, SP Balcerzak, SR Dakhil, TP Miller, KS Lanier, RA Chapman, RI Fisher. <u>Journal of Clinical Oncology</u> 21(10):1996-2003, 2003.	Lymphoma	4/1/95	2/15/96
S9911 (1999)	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular Non-Hodgkin's lymphoma. Southwest Oncology Group protocol S9911. OW Press, JM Unger, RM Brazier, DG Maloney, TP Miller, M LeBlanc, ER Gaynor, SE Rivkin, RI Fisher. <u>Blood</u> 102(5):1606-1612, 2003.	Lymphoma	5/15/99	6/1/00
Multiple Studies (1866)	Directed indices for exploring gene expression data. M LeBlanc, C Kooperberg, TM Grogan, TP Miller. <u>Bioinformatics</u> 19(6):686-693, 2003.	Lymphoma Lymph Bio		
None (2109)	Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. RI Fisher. <u>Seminars in Oncology</u> 30(2) Suppl 4:3-9, 2003.			

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8819 (2133)	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, WC Chan, T Zhao, C Haioun, TC Greiner, DD Weisenburger, JC Lynch, JM Vose, JO Armitage, EB Smeland, S Kvaloy, H Holte, J Delabie, E Campo, E Montserrat, A Lopez-Guillermo, G Ott, K Muller-Hermelink, JM Connors, R Braziel, TM Grogan, RI Fisher, TP Miller, M LeBlanc, M Chiorazzi, H Zhao, L Yang, J Powell, WH Wilson, ES Jaffe, R Simon, RD Klausner, JM Staudt. <u>Blood</u> 102(11):#208, 2003.	Lymph	2/15/89	OPEN
9239 (2045)	Phase II study of sequential reduction in immunosuppression interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder (PTLD) (SWOG/ECOG S9239). LJ Swinnen, M LeBlanc, Y Kasamon, T Grogan, L Gordon, TP Miller, RI Fisher. <u>Blood</u> 102(11):#1463, 2003.	Lymphoma	4/15/95	8/15/00
9320 (2044)	Phase II study of ProMACE CytaBOM with trimethoprim sulfamethoxazole, granulocyte colony stimulating factor (G-CSF) and antiretroviral therapy in patients with AIDS related Non Hodgkin's lymphoma (AIDS-NHL), (S9320). LJ Swinnen, E Gaynor, M LeBlanc, MJ Lechowicz, J Unger, TP Miller, TM Grogan, RI Fisher. <u>Blood</u> 102(11):#1462, 2003.	Lymph	5/1/94	12/1/00
S9911 (2021)	CHOP followed by tositumomab/iodine I 131 tositumomab (Bexxar®) for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: a phase II trial of the Southwest Oncology Group (S9911). OW Press, JM Unger, RM Braziel, DG Maloney, TP Miller, M LeBlanc, RI Fisher. <u>Blood</u> 102(11):#90, 2003.	Lymph	5/15/99	6/1/00
Multiple Studies (2026)	Gene expression microarray analysis of de novo CD5+ diffuse large B cell lymphoma (LLMPP): a distinct entity? RD Gascoyne, S Dave, A Zettl, S Bea, WC Chan, A Rosenwald, ES Jaffe, E Campo, J Delabie, D Weisenburger, G Ott, K Muller-Hermelink, L Rimsza, T Grogan, JM Connors, G Wright, LM Staudt. <u>Blood</u> 102(11):#621,2003.	Lymph		
S8819 (2024)	Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival: a follow-up study to the NIH director's challenge leukemia and lymphoma molecular profiling project (LLMPP). L Rimsza, R Roberts, T Miller, J Unger, M LeBlanc, R Braziel, D Weisenburger, WC Chan, T Greiner, K Muller-Hermelink, E Jaffe, RD Gascoyne, E Campo, D Fuchs, C Spier, R Fisher, L Staudt, T Grogan. <u>Blood</u> 102(11):#1417, 2003.	Lymph		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (2025)	Loss of major histocompatibility class II (MHCII) expression in nodal diffuse large B cell lymphoma (DLBCL) is highly coordinated and unlikely related to chromosomal deletions. L Rimsza, R Roberts, E Campo, T Grogan, S Bea, I Salaverria, A Zettl, R Fisher, J Unger, M LeBlanc, L Staudt, R Gascoyne, W Chan, D Weisenburger, T Greiner, E Jaffe, R Braziel, K Mueller-Hermelink, T Miller. <u>Blood</u> 102(11):#3321, 2003.	Lymph		
None (2110)	Editorial: Seminars in Oncology. RI Fisher. <u>Seminars in Oncology</u> 30(2) Suppl 4:1-2, 2003.			

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8819 (1853)	Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma study group based on 61 cases. SA Pileri, TM Grogan, NL Harris, P Banks, E Campo, JKC Chan, RD Favera, G Delsol, C De Wolf-Peeters, B Falini, RD Gascoyne, P Gaulard, KC Gatter, PG Isaacson, ES Jaffe, P Kluin, DM Knowles, DY Mason, S Mori, HK Muller-Hermelink, MA Piris, E Ralfkiaer, H Stein, IJ Su, RA Warnke, LM Weiss. <u>Histopathology</u> 41:1-29, 2002.	Lymph	2/15/89	OPEN
8819 (1846)	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, RD Gascoyne, HK Muller-Hermelink, EB Smeland, LM Staudt, TM Grogan, TP Miller, M LeBlanc. <u>New England Journal of Medicine</u> 346(25):1937-1947, 2002.	Lymph	2/15/89	OPEN
ABSTRACTS PUBLISHED/PRESENTED				
8819 (1814)	Failure of beta-globin gene detection does not predict non-amplification of DNA in JH/Bcl-2 PCR analysis: insights from a national follicular lymphoma clinical trial. G Fan, RM Brazier, T Grogan. <u>Modern Pathology</u> 15(1):240a (#1002), 2002.	Lymph	2/15/89	OPEN
8819 (1815)	Gene expression profiling in laser microdissected normal follicular mantles, mantle cell lymphoma (MCL), and blastoid variant of mantle cell lymphoma. S de Vos, U Krug, WK Hofman, GS Pinkus, Sh Swerdlow, W Wachsman, T Grogan, C Yue, HP Koeffler, JW Said. <u>Modern Pathology</u> 15(1):237a (#991), 2002.	Lymph	2/15/89	OPEN
8819 (1868)	Major histocompatibility complex (MHC) class II antigen HLA-DR gene expression levels in diffuse large B-cell lymphoma correlate with survival. TP Miller, M LeBlanc, TM Grogan, RM Brazier, LM Staudt, RI Fisher. <u>Blood</u> 100(11):346a, (#1341), 2002.	Lymph	2/15/89	OPEN
Multiple Studies (1867)	Was the bimodal age incidence of Hodgkin's lymphoma a result of mistaken diagnoses of non-Hodgkin's Lymphoma? TP Miller, M LeBlanc, RM Brazier, TM Grogan, O Press, RI Fisher. <u>Blood</u> 100(11):771a, (#3048), 2002.	Lymph Lymph Bio		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9125/9240 (1624)	Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma. A Southwest Oncology Group study. ER Gaynor, JM Unger, TP Miller, TM Grogan, LA White, Jr, GM Mills, SP Balcerzak, M Varterasian, M LeBlanc, RI Fisher. <u>Journal of Clinical Oncology</u> 19(3):750-755, 2001	Lymphoma	6/1/91	2/15/93
9133 (1710)	Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA-IIA Hodgkin's disease. OW Press, M LeBlanc, AS Lichter, TM Grogan, JM Unger, TH Wasserman, ER Gaynor, BA Peterson, TP Miller, RI Fisher. <u>Journal of Clinical Oncology</u> 19(22):4238-4244, 2001.	Lymphoma	9/15/92	4/24/00
Multiple Studies (1916)	Editorial: Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. RI Fisher. <u>Journal of the National Cancer Institute</u> 93(1):4-5, 2001.	Lymphoma		
Multiple Studies (1902)	Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. PG Murray, LJ Swinnen, JR Flavell, MV Ragni, KRN Baumforth, SM Toomey, AH Filipovich, D Lowe, CS Schnell, J Johl, M Gulley, LS Young, RF Ambinder. <u>Human Pathology</u> 32(9):963-969, 2001.	Lymphoma		
Multiple Studies (1673)	The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. RM Brazier, DA Arber, ML Slovak, ML Gulley, C Spier C Kjeldsberg, J Unger, TP Miller, R Tubbs, C Leith, RI Fisher, TM Grogan. <u>Blood</u> 97(12):3713-3720, 2001.	Lymphoma		
Multiple Studies (1891)	Tumours of haematopoietic and lymphoid tissues. T Grogan. In: <u>World Health Organization Classification of Tumours; Pathology & Genetics</u> . ES Jaffe, NL Harris, H Stein, JW Vardiman (Eds). IARC Press: Lyon, 2001.	Lymph Lymph Bio		
Multiple Studies (1812)	Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. WT Bellamy, L Richter, D Sirjani, C Roxas, B Glinsmann-Gibson, Y Frutiger, TM Grogan, AF List. <u>Blood</u> 97(5):1427-1434, 2001.	Lymph Lymph Bio Leuk Leuk Bio		
ABSTRACTS PUBLISHED/PRESENTED				
8736	CHOP alone compared to CHOP plus radiotherapy for	Lymphoma	3/15/88	6/15/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1775)	early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. TP Miller, M LeBlanc, C Spier, E Chase, RI Fisher. <u>Blood</u> 98(11):724a-725a, (#3024), 2001.			
8819 (1865)	Alteration of SMRT tumor suppressor function in transformed Non-Hodgkin Lymphomas. LJ Coignet, L Song, A Zlobin, C Brigaudeau, S Weijsen, Q Jiang, E Nacheva, E Davis, D Catovsky, T Grogan L Staudt, RI Fisher, L Miele. <u>Blood</u> 98(11):760a (#3164), 2001.	Lymph Lymph Bio	2/15/89	OPEN
8819 (1816)	Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. AF Baker, WT Bellamy, BJ Glinsmann-Gibson, R Heaton, A Buresh, TM Grogan, AF List. <u>Blood</u> 98(11):353a, (#1490), 2001.	Lymphoma	2/15/89	OPEN
8819 (1774)	Cellular proteins determined by immunohistochemistry predict outcome in patients with aggressive non-Hodgkin's lymphoma: a first generation model of risk. TP Miller, TM Grogan, J Unger, R Brazier, M Jaramillo, RI Fisher. <u>Blood</u> 98(11):125a, (#526), 2001.	Lymphoma	2/15/89	OPEN
9133 (1768)	A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). OW Press, M LeBlanc, A Lichter, TH Wasserman, J Unger, T Miller, RI Fisher. <u>Leukemia & Lymphoma</u> 42 (Suppl 2):52 (#P-089), 2001.	Lymphoma	9/15/92	4/24/00
9349 (1772)	Dose-intense CHOPx2 therapy of intermediate grade lymphoma – a phase II study of the Southwest Oncology Group (SWOG). DW Blayney, ML LeBlanc, RI Fisher. <u>Blood</u> 98(11):343a, (#1448), 2001.	Lymphoma	9/15/94	1/15/97
S9800 (1773)	A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. DG Maloney, OW Press, RM Brazier, JM Unger, ML LeBlanc, TM Grogan, TP Miller, RI Fisher. <u>Blood</u> 98(11):843a, (#3502), 2001.	Lymphoma	2/15/98	11/15/98
S9911 (1771)	A phase II trial of CHOP followed by Bexxar™ (tositumomab and Iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). OW Press, JM Unger, RM Brazier, DG Maloney, ML LeBlanc, TM Grogan, TP Miller, RI Fisher. <u>Blood</u> 98(11):843a-844a, (#3504), 2001.	Lymphoma	5/15/99	6/1/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8809 (1558)	Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. RI Fisher, BW Dana, M LeBlanc, C Kjeldsberg, JD Forman, JM Unger, SP Balcerzak, ER Gaynor, V Roy, T Miller. <u>Journal of Clinical Oncology</u> 18(10):2010-2016, 2000.	Lymphoma	10/1/88	11/15/94
9219 (1668)	Phase II evaluation of interleukin-4 in patients with Non-Hodgkin's lymphoma: a Southwest Oncology Group trial. CW Taylor, M LeBlanc, RI Fisher, DF Moore, Sr, RW Roach, L Elias, TP Miller. <u>Anti-Cancer Drugs</u> 11:695-700, 2000.	Lymphoma	8/1/94	8/1/99
Multiple Studies (1746)	Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. RI Fisher. <u>Seminars in Oncology</u> 27(6) Suppl 12:2-8, 2000.	Lymph		
ABSTRACTS PUBLISHED/PRESENTED				
*9133 (1671)	A phase III randomized Intergroup trial of subtotal lymphoid irradiation (STLI) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). OW Press, M LeBlanc, A Lichter, TH Wasserman, T Miller, R Fisher. <u>Blood</u> 96(11):575a (#2471), 2000	Lymphoma	9/15/92	4/24/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8515 (1078)	Phase II trial of menogaril in non-hodgkin's lymphomas: a Southwest Oncology Group trial. DF Moore, Jr, TD Brown, M LeBlanc, S Dahlberg, TP Miller, S McClure, RI Fisher. <u>Investigational New Drugs</u> 17(2):169-172, 1999.	Lymphoma	3/15/88	12/15/91
8819 (1811)	Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. WT Bellamy, L Richter, Y Frutiger, TM Grogan. <u>Cancer Research</u> 59(3): 728-733, 1999.	Lymph Lymph Bio	2/15/89	OPEN
8819 (1810)	Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's Lymphomas. AE Kossakowska, DR Edwards, C Prusinkiewicz, MC Zhang, D Guo, SJ Urbanski, T Grogan, LA Marquez, A Janowska-Wieczorek. <u>Blood</u> 94(6):2080-2089, 1999.	Lymph Lymph Bio	2/15/89	OPEN
None (1591)	Methylation status of the Epstein-Barr virus major latent promoter C in latrogenic B cell lymphoproliferative disease. Q Tao, LJ Swinnen, J Yang, G Srivastava, KD Robertson, FR Ambinder. <u>American Journal of Pathology</u> 155(2):619-625, 1999.	Lymphoma		
None (1577)	Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. BD Cheson, SJ Horning, B Coiffier, MA Shipp, RI Fisher, JM Connors, TA Lister, J Vose, A Grillo-Lopez, A Hagenbeek, F Cabanillas, D Klippensten, W Hiddemann, R Castellino, NL Harris, JO Armitage, W Carter, R Hoppe, GP Canellos. <u>Journal of Clinical Oncology</u> 17(4):1244-1253, 1999.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*9239 (1574)	Bcl-6 is not overexpressed in post-transplant lymphoproliferative disorder (PTLD). CC Ye, LJ Swinnen, H Fan, TM Grogan, ML Gulley. <u>Blood</u> 94(10) Suppl 1:519a (#2322), part 1 of 2, 1999.	Lymphoma	4/15/95	OPEN
*9239/9320 (1573)	Frequent expression of the tumor necrosis factor receptor associated factor-1 in LMP1-positive post transplant lymphoproliferative disease and HIV-associated lymphomas. PG Murray, LJ Swinnen, JR Flavell, MV Ragni, HT Hassan, D Lowe, C Schnell, J Johl, LS Young, RF Ambinder. <u>Blood</u> 94(10) Suppl 1:303a (#1353), part 1 of 2, 1999.	Lymphoma	4/15/95	OPEN
*9501 (1501)	SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy. W Velasquez, D Lew, T Miller, R Fisher. <u>Proc of the American Society of Clinical Oncology</u> 18:9a (#27), 1999.	Lymphoma	4/1/95	2/15/96
Multiple	Burkitt-like lymphoma: a distinctive morphology and	Lymphoma		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Studies (1684)	phenotype with poor prognosis. R Brazier, D Arber, T Miller, R Fisher, T Grogan. <u>Modern Pathology</u> 12(1):132A (#771), 1999.			

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7204/7426/ 7713 (1433)	New REAL clinical entities. RI Fisher, TP Miller, TM Grogan <u>The Cancer Journal from Scientific American</u> 4 (Suppl 2): S5-S12, 1998.	Lymphoma		
7961/8516/ 7808 (1572)	Treatment of grey zone lymphomas. RI Fisher. <u>Annals of Oncology</u> 9(5):S121-S123, 1998.	Lymphoma		
8516 (1308)	BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. JN Winter, J Andersen, JC Reed, S Krajewski, D Variakojis, KD Bauer, RI Fisher, LI Gordon, MM Oken, S Jiang, D Jeffries, P Domer. <u>Blood</u> 91(4):1391-1398, 1998.	Lymphoma	4/4/86	6/15/91
8736 (1354)	Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. TP Miller, S Dahlberg, JR Cassady, DJ Adelstein, CM Spier, TM Grogan, M LeBlanc, S Carlin, E Chase, RI Fisher. <u>New England Journal of Medicine</u> 339:21-26, 1998.	Lymphoma	3/15/88	6/15/95
8796 (1365)	MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. JH Glick, MLYoung, D Harrington, RL Schilsky, T Beck, R Neiman, RI Fisher, BA Peterson, MM Oken. <u>Journal of Clinical Oncology</u> 16(1):19-26, 1998.	Lymphoma	12/1/87	8/1/89
8942 (1235)	Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens-A Southwest Oncology Group trial. PJ Stiff, S Dahlberg, SJ Forman, AR McCall, SJ Horning, AP Nademanee, KG Blume, M LeBlanc, RI Fisher. <u>Journal of Clinical Oncology</u> 16(1):48-55, 1998.	Lymphoma	3/1/90	12/15/94
9239 (1482)	To the editor-in-chief. Q Tao, RF Ambinder, LJ Swinnen. <u>American Journal of Pathology</u> 152(5):1398-1399, 1998.	Lymphoma	4/15/95	Open
9246 (1315)	Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. OW Press, M LeBlanc, TJ O'Rourke, S Gagnet, RA Chapman, SP Balcerzak, RI Fisher. <u>Journal of Clinical Oncology</u> 16(2):574-578, 1998.	Lymphoma	3/1/93	12/1/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9246 (1397)	Paclitaxel for the treatment of lymphoma. A Younes. <u>Journal of Clinical Oncology</u> 16(6): 2289-2290, 1998.	Lymphoma	3/1/93	12/1/95
9246 (1527)	Paclitaxel for the treatment of lymphoma.In reply. OW Press. <u>Journal of Clinical Oncology</u> 16(6): 2290, 1998.	Lymphoma	3/1/93	12/1/95
ABSTRACTS PUBLISHED/PRESENTED				
8736 (1489)	Treatment of early stage intermediate and high grade lymphomas. TP Miller, M LeBlanc, RI Fisher. <u>Annals of Hematology</u> 77 (Suppl 1):A18 (#69), 1998.	Lymphoma	3/15/88	6/15/95
*8809 (1370)	A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809). BW Dana, J Unger, RI Fisher. <u>Proc of the American Society of Clinical Oncology</u> 17:3a (#10), 1998.	Lymphoma	10/1/88	11/15/94
8809 (1488)	A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809). RI Fisher, J Unger, BW Dana. <u>Annals of Hematology</u> 77 (Suppl 1):A9 (#36), 1998.	Lymphoma	10/1/88	11/15/94
*9239 (1462)	EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients. LJ Swinnen, ML Gulley, E Hamilton, SA Schichman. <u>Blood</u> 92(10) (Suppl 1):314a-315a (#1291), 1998.	Lymphoma	4/15/98	Open
Multiple Studies (1571)	A prognostic score for advanced hodgkin's disease. D Hasenclever, V Diehl, JO Armitage, D Assouline, M Bjorkholm, E Brusamolino, GP Canellos, P Carde, D Crowther, D Cunningham, H Eghbali, C Ferme, RI Fisher, HJ Glick, B Glimelius, PG Gobbi, H Holte, SJ Horning, TA Lister, DL Longo, F Mandelli, A Polliack, SJ Proctor, L Specht, JW Sweetenham, GV Hudson. <u>New England Journal of Medicine</u> 339(21):1506-1514, 1998.	Lymphoma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7204/7426 7713 (1310)	Follicular lymphomas: Do histologic subtypes predict outcome? TP Miller, M LeBlanc, TM Grogan, RI Fisher. <u>Hematology/Oncology Clinics of North America</u> 11(5): 893-900, 1997.	Lymphoma		
8516 (1338)	Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. RI Fisher. <u>Cancer Chemotherapy and Pharmacology</u> 40(Suppl): S42-S46, 1997.	Lymphoma	4/4/86	6/15/91
8736 (1178)	CHOP plus radiotherapy is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma: A Southwest Oncology Group study. TP Miller, S Dahlberg, JR Cassady, DJ Adelstein, CM Spier, TM Grogan, S Carlin, E Chase, M LeBlanc, RI Fisher. <u>Adjuvant Therapy of Cancer VIII, 1997</u> SE Salmon eds, Lippincott-Raven Publishers 27:245-250. 1997.	Lymphoma	3/15/88	6/15/95
Multiple Studies (1342)	A Southwest Oncology Group perspective on the revised European-American lymphoma classification. TM Grogan, TP Miller, RI Fisher. <u>Hematology/Oncology Clinics of North America</u> 11(5): 819-846, 1997.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*9239 (1350)	Conservation of Epstein-Barr virus (EBV) CTL epitopes in EVB(+) post transplant lymphomas in solid organ transplant recipients. Q Tao, L Swinnen, RF Ambinder. <u>Blood</u> 90 (10) Suppl 1:512a (#2281), 1997.	Lymphoma	4/15/95	Open
8952 (1405)	MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). D Duggan, G Petroni, J Johnson, K Hanson, J Glick, JM Connors, R Chemy, M Bracos, BA Peterson. <u>Proc of the American Society of Clinical Oncology</u> 16:12a (#43), 1997.	Lymphoma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7204/7426 7713 (1206)	Clinical course and therapy of mantle cell lymphoma. RI Fisher, OW Press, TP Miller, TM Grogan. <u>Principles & Practice of Oncology</u> 10(6):1-7, 1996.	Lymphoma		
7204/7426 7713 (1205)	Evaluation and management of mantle cell lymphoma. OW Press, TM Grogan, RI Fisher. <u>Advances in Leukemia and Lymphoma</u> 6(1):3-11, 1996.	Lymphoma		
7204/7426 7713 (1211)	Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. BW Dana, S Dahlberg, BN Nathwani, E Chase, C Coltman, TP Miller, RI Fisher. <u>Classic Papers and Current Comments</u> 1(2):320-328, 1996.	Lymphoma		
7204/7426 7713 (1207)	Mantle-cell lymphoma: Classification and therapeutic implications. RI Fisher. <u>Annals of Oncology</u> 7 (Suppl 6): S35-S39, 1996.	Lymphoma		
7808 (1204)	Report of workshop 5: Early high-dose chemotherapy. RI Fisher. <u>Annals of Oncology</u> 7(Suppl 4):S131-S133, 1996.	Lymphoma	6/1/78	12/1/87
8516 (1248)	Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. JN Winter, J Andersen, D Variakojis, LI Gordon, RI Fisher, MM Oken, RS Neiman, S Jiang, KD Bauer. <u>Blood</u> 88(10): 3919-3925, 1996.	Lymphoma	4/4/86	6/15/91
Multiple Studies (1208)	Lymphoma classification - The gap between biology and clinical management is closing. W Hiddemann, DL Longo, B Coiffier, RI Fisher, F Cabanillas, F Cavalli, LM Nadler, VT De Vita, TA Lister, JO Armitage. <u>Blood</u> 88(11):4085-4089, 1996.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*8736 (1166)	CHOP plus radiotherapy (RT) is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study. TP Miller, S Dahlberg, JR Cassady, C Spier, TM Grogan, S Carlin, E Chase, RI Fisher. <u>Proc 8th International Conference on the Adjuvant Therapy of Cancer</u> p47 (#27), 1996.	Lymphoma	3/15/88	6/15/95
8736 (1282)	Superiority of a brief course of CHOP plus radiotherapy (RT) over CHOP alone in localized unfavorable non-Hodgkin's lymphoma (NHL) is seen in lowest risk subgroups: A Southwest Oncology Group study. TP Miller, S Dahlberg, JR Cassady, C Spier, TM Grogan, S Carlin, E Chase, RI Fisher. <u>Annals of Oncology</u> 7(3):23 (#076), 1996.	Lymphoma	3/15/88	6/15/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8736 (1141)	Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study. TP Miller, S Dahlberg, JR Cassady, C Spier, TM Grogan, S Carlin, E Chase, RI Fisher. <u>American Society of Clinical Oncology</u> 15:411 (#1257), 1996.	Lymphoma	3/15/88	6/15/95
*9011 (1203)	Single fraction high dose chemotherapy with or without total body irradiation (TBI) and an autologous bone marrow transplant (ABMT) for patients with relapsed/ refractory Hodgkin's disease: High survival rate in chemoresistant disease. A Southwest Oncology Group (SWOG) trial. PJ Stiff, J Unger, RI Fisher, A McCall, A Nademanee, K Blume, S Horning, SJ Forman. <u>Blood</u> 88(10) Suppl 1:485a (#1930), 1996.	Lymphoma	4/15/90	12/1/95
*9125/9240 (1167)	Infusional therapy with first generation chemosensitizers (CS) results in increased toxicity without improved benefit in untreated lymphoma. ER Gaynor, TP Miller, S Dahlberg, M LeBlanc, RI Fisher. <u>American Society of Clinical Oncology</u> 15:413 (#1265), 1996.	Lymphoma	1/15/93	2/1/94
*Multiple Studies (1159)	Clinical behavior of 2,168 patients treated on Southwest Oncology Group (SWOG) protocols and reclassified according to the REAL classification. RI Fisher, TM Grogan, S Dahlberg, R Brazier, P Banks, B Nathwani, C Kjeldsberg, TP Miller. <u>Annals of Oncology</u> 7 (Suppl 3) (#006), 1996.	Lymphoma		
Multiple Studies (1187)	Morphologic review of 2100 SWOG patients supports the REAL classification of lymphoma as clinically useful. T Grogan, T Miller, S Dahlberg, R Brazier, P Banks, B Nathwani, C Kjeldsberg, R Tubbs, K Foucar, C Leith, C Spier, B Schnitzer, M Gulley, R Fisher. <u>International Academy of Pathology Book of Abstracts</u> 112A (#650), 1996.	Lymphoma		
*Multiple Studies (1283)	NCAM-Associated tumors: Are they a discrete group of disorders? TP Miller, TM Grogan. <u>Lymphoma Conference Program & Summaries</u> , San Antonio, Texas, 1995.	Lymphoma		
Multiple Studies (1160)	REAL classification of lymphoma allows improved delineation of histologic risk groups: A Southwest Oncology Group (SWOG) study. TM Grogan, TP Miller, S Dahlberg, R Brazier, P Banks, B Nathwani, C Kjeldsberg, R Tubbs, RI Fisher. <u>American Society of Clinical Oncology</u> 15:425 (#1310), 1996.	Lymphoma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7204/7426 7713 (1026)	A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories). RI Fisher, S Dahlberg, BN Nathwani, PM Banks, TP Miller, TM Grogan. <u>Blood</u> 85(4):1075-1082, 1995.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
8516/8819 (INT-0067) (1081)	A Southwest Oncology Group (SWOG) analysis of the anaplastic large cell lymphoma (ALCL) entities in the revised European American lymphoma (REAL) classification. T Grogan, C Kjeldsberg, R Tubbs, S Dahlberg, R Brazier, C Foucar, C Leith, C Spier, E Gaynor, T Miller, R Fisher. <u>International Academy of Pathology</u> 111A (#644), 1995.	Lymphoma	4/4/86	6/15/91
*8942 (1087)	Autologous bone marrow transplantation (ABMT) for patients with diffuse non-Hodgkin's lymphoma: Value of augmented preparative regimens. A Southwest Oncology Group (SWOG) trial. P Stiff, S Dahlberg, RI Fisher, A McCall, A Nademanee, SJ Forman, S Horning, K Blume. <u>ASCO</u> 14:388 (#1209), 1995.	Lymphoma	3/1/90	12/15/94

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7808 (426)	Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. CJ Fabian, CM Mansfield S Dahlberg, SE Jones, TP Miller, EV Slyck, PN Grozea, FS Morrison, CA Coltman, RI Fisher. <u>Annals of Internal Medicine</u> 120(11):903- 912, 1994.	Lymphoma	6/1/78	12/1/87
8309 (867)	Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group study. R Saez, S Dahlberg, FR Appelbaum, RJ Hartsock, F LeMaistre, CA Coltman, Jr, RI Fisher. <u>Hematological Oncology</u> 12(2):75-85, 1994.	Lymphoma	10/3/84	5/1/89
8516 (INT-0067) (985)	A phase III comparison of CHOP vs. m-BACOD vs. Pro-MACE-CytaBOM vs. MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the national high-priority lymphoma study. RI Fisher, ER Gaynor, S Dahlberg, MM Oken, TM Grogan, EM Mize, JH Glick, CA Coltman, Jr, TP Miller. <u>Annals of Oncology</u> 5 (Suppl 2):S91-S95, 1994.	Lymphoma	4/4/86	6/15/91
8516/8819 (913)	Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group (SWOG) trial. TP Miller, TM Grogan, S Dahlberg, CM Spier, RM Braziel, PM Banks, K Foucar, CR Kjeldsberg, N Levy, BN Nathwani, B Schnitzer, RR Tubbs, ER Gaynor, RI Fisher. <u>Blood</u> 83(6):1460-1466, 1994.	Lymphoma CCR		
8819 (918)	The presence of bcl-1 and bcl-2 gene rearrangements in diffuse small cleaved cell lymphoma: A disease with diverse molecular and immunophenotypic findings. CP Leith, CL Willman, CM Spier, TP Miller, TM Grogan. <u>Diagnostic Molecular Pathology</u> 3(3):178-183, 1994.	Lymphoma CCR	2/15/93	Open
ABSTRACTS PUBLISHED/PRESENTED				
7204/7426 7713 (953)	A clinical analysis of new indolent lymphoma entities in the revised European American lymphoma (REAL) classification. RI Fisher, S Dahlberg, TM Grogan. <u>ASCO</u> 13:379 (#1287), 1994.	Lymphoma		
*8410/8503 8508/8516 (957)	African Americans treated on SWOG NHL studies: Similar incidence, received dose intensity, and outcome to Caucasian patients. S Dahlberg, RI Fisher, CA Coltman. <u>ASCO</u> 13:370 (#1251), 1994.	Lymphoma		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8516 (INT-0067) (958)	Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B. ER Gaynor, S Dahlberg, RI Fisher. <u>ASCO</u> 13:370 (#1250), 1994.	Lymphoma	04/04/86	06/15/91
8819 (945)	Polysialated NCAM as a neurodeterminant in malignant lymphoma (ML). T Grogan, J Guptil, J Mullen, J Ye, E Hanneman, L Vela, Y Frutiger, T Miller, F Troy. <u>Lab Investigation</u> 70(1):110A(#637), 1994.	Lymphoma	2/15/89	Open
*8907 (1024)	Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkin's lymphomas. TP Miller, S Dahlberg, TM Grogan, RI Fisher. <u>Anti-Cancer Drugs</u> 5 (Suppl 1):73 (#166), 1994.	Lymphoma	7/1/89	12/15/91

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7204/7426 7713 (788)	Long-term followup of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. BW Dana, S Dahlberg, BN Nathwani, E Chase, CA Coltman, Jr, TP Miller, RI Fisher. <u>JCO</u> 11(4): 644-651, 1993.	Lymphoma		
7204/7426 7713 (899)	Treatment of diffuse large-cell lymphoma: A summary of outcome for patients treated by the Southwest Oncology Group. TP Miller, S Dahlberg. In: <u>Malignant Lymphomas Including Hodgkin's disease: diagnosis, management and special problems</u> , Dana BW, ed., Kluwer Academic Publishers, Boston, Vol.4, pp. 53-63, 1993.	Lymphoma		
8410/8503 8508 (930)	A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. <u>NEJM</u> 329(14):987-994, 1993.	Lymphoma		
8516 (INT-0067) (790)	Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. RI Fisher, ER Gaynor, S Dahlberg, MM Oken, TM Grogan, EM Mize, JH Glick, CA Coltman, Jr, TP Miller. <u>NEJM</u> 328: 1002-1006, 1993.	Lymphoma	04/04/86	06/15/91
8819 (928)	Cytolytic (TIA-1 +) tumor infiltrating lymphocytes in B cell non-Hodgkin's lymphomas. J Diaz, R Tubbs, M Stoler, T Grogan. <u>Leukemia & Lymphoma</u> 9: 91-94, 1993.	Lymphoma CCR	02/15/89	Open
8819 (929)	Immunobiologic correlates of prognosis in lymphoma. TM Grogan, TP Miller. <u>Seminars in Oncology</u> 20:58-74, 1993.	Lymphoma CCR	02/15/89	Open
8819 (917)	NCAM (CD56)-positive malignant lymphoma. WF Kern, CM Spier, TP Miller, TM Grogan. <u>Leukemia and Lymphoma</u> 12:1-10, 1993.	Lymphoma CCR	02/15/89	Open

ABSTRACTS PUBLISHED/PRESENTED

Multiple Studies (1011)	The proliferative rate of aggressive non-Hodgkin's lymphomas identifies a patient group with fatal disease: A prospective Southwest Oncology Group trial. T Grogan, R Brazier, P Banks, K Foucar, N Levy, B Nathwani, R Tubbs, C Kjeldsberg, R Schnitzer, C Spier, T Miller. <u>International Academy of Pathology</u> 68:91A (#525), 1993.	Lymphoma
-------------------------------	---	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7808 (683)	Role of additional radiotherapy in advanced stages of Hodgkin's disease. JH Meerwaldt, CN Coleman, RI Fisher, TA Lister, V Diehl. <u>Annals of Oncology</u> 3 (Suppl 4):S83-S85, 1992.	Lymphoma	06/01/78	12/01/87
8819 (540)	Neural cell adhesion molecule-positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement. WF Kern, CM Spier, EH Hanneman, TP Miller, M Matzner, TM Grogan. <u>Blood</u> 79(9):2432-2437, 1992.	Lymphoma CCR	02/15/89	Open
8819 (542)	Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large cell anaplastic lymphomas using the polymerase chain reaction. CW Ross, JA Schlegelmilch, TM Grogan, LM Weiss, B Schnitzer, CA Hanson. <u>American Journal of Pathology</u> 141:457-465, 1992.	Lymphoma CCR	02/15/89	Open
8819 (543)	Determination of T-cell monoclonality in non-Hodgkin's lymphoma by frozen section immunohistology. J Diaz, G Segal, R Tubbs, M Stoler, T Grogan. <u>Leukemia-Lymphoma</u> 8:477-481, 1992.	Lymphoma CCR	02/15/89	Open
8819 (781)	Diffuse small cleaved cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets. CP Leith, CM Spier, TM Grogan, G Gonzales, CS Rangel, JA Rybski, M Matzner, TP Miller. <u>JCO</u> 10:1259-1265, 1992.	Lymphoma CCR	02/15/89	Open
ABSTRACTS PUBLISHED/PRESENTED				
7808 (670)	Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease: A randomized Southwest Oncology Group study. CM Mansfield, C Fabian, S Dahlberg, SE Jones, TP Miller, E van Slyck, PN Grozea, FS Morrison, CA Coltman Jr, RI Fisher. <u>International Journal of Radiation Oncology, Biology and Physics</u> 21(Suppl 1):191 (#142), 1992.	Lymphoma	06/01/78	12/01/87
*8410/8503 8508 (820)	Development of a predictive model for aggressive lymphoma. The International NHL prognostic factors project. N Shipp, D Harrington, J Anderson, J Armitage, G Bonadonna, G Brittinger, F Cabanillas, G Canellas, R Coiffier, J Connors, R Cowan, C Crowther, M Engelhard, R Fisher, C Gisselbrecht, E Horning, E Lepage, A Lister, J Meerwaldt, E Montserrat, N Nissen, M Oken, B Peterson, C Tondini, W Valasquez, B Yeap. <u>ASCO</u> 11:319 (#1084), 1992.	Lymphoma	07/20/84	02/22/85

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8516 (825)	A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067). RI Fisher, E Gaynor, S Dahlberg, EM Mize, M Oken. <u>ASCO</u> 11:315 (#1067), 1992.	Lymphoma	04/04/86	06/15/91
8819 (840)	Diffuse small cleaved cell lymphoma (DSCL): Correlation of BCL-1 and BCL-2 gene rearrangements with survival. C Leith, C Willman, C Spier, T Miller, T Grogan. <u>Modern Pathology</u> 5(1):81A (#478), 1992.	Lymphoma CCR	02/15/89	Open
8819 (841)	Lineage restricted MDR1 expression in normal blood cells. WT Klimecki, BW Futscher, LL Blake, TM Grogan, WS Dalton. <u>AACR</u> 33:467 (#2791), 1992.	Lymphoma CCR	02/15/89	Open
8819 (842)	Molecular analysis of CD3(+) and CD3(-) peripheral T-cell lymphomas (RTCL). E Hammer, P Suwanjindar, R Brazier. <u>Modern Pathology</u> 5:78A (#458), 1992.	Lymphoma CCR	02/15/89	Open
*Multiple Studies (847)	The proliferative rate of aggressive non-Hodgkin's lymphomas identifies a patient group with fatal disease: A prospective Southwest Oncology Group trial. TP Miller, S Dahlberg, TM Grogan, C Spier, E Gaynor, RI Fisher. <u>ASCO</u> 11:315 (#1066), 1992.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8112/8245 (549)	Alternated versus syncopated CHOP-CVB. Two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. L Dabich, S Dahlberg, RJ Hartsock, AF LoBuglio, MK Liepman, PN Grozea, HJ Eyre, JK Weick, JD Bonnet, CA Coltman, Jr, RI Fisher. <u>Cancer Investigation</u> 9(6): 613-620, 1991.	Lymphoma	01/05/82	03/16/84
8406 (440)	Activity of esorubicin in recurrent malignant lymphoma: A Southwest Oncology Group study. TP Miller, S Dahlberg, SK Williamson, RJ Belt, B Dana, RI Fisher. <u>JCO</u> 9:1204-1209, 1991.	Lymphoma	08/17/84	03/15/88
8503 (488)	Long term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. RI Fisher, DL Long, VT DeVita, SM Hubbard, TP Miller, RC Young. <u>Ann Oncol</u> 2 (suppl 1):33-35, 1991.	Lymphoma	04/26/85	11/15/85
8508 (395)	Combination chemotherapy of intermediate-grade - and high grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group study. JK Weick, S Dahlberg, RI Fisher, B Dana, TP Miller, SP Balcerzak, HI Pierce. <u>JCO</u> 9(5):748-753, 1991.	Lymphoma	11/06/85	06/01/86
8819 (494)	New biologic markers in non-Hodgkin's lymphomas. TM Grogan, TP Miller. <u>Hematology/Oncology Clinics of North America</u> 5(5):925-933, 1991.	Lymphoma	02/15/89	Open
8819 (495)	Patients with localized non-Hodgkin's lymphomas provide opportunities for future research. TP Miller, TM Grogan. <u>Oncology</u> 5(8):127-132, 1991.	Lymphoma	02/15/89	Open
8819 (541)	Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-A, B, C) phenotype. JA Rybski, CM Spier, TP Miller, SM Lippman, DL McGee, TM Grogan. <u>Leukemia-Lymphoma</u> 6:31-38, 1991.	Lymphoma	02/15/89	Open
Multiple Studies (497)	P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. TP Miller, TM Grogan, WS Dalton, CM Spier, RJ Scheper, SE Salmon. <u>JCO</u> 9(1):17-24, 1991.	Lymphoma		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
7808 (558)	Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease. A randomized Southwest Oncology Group study. CM Mansfield, C Fabian, S Dahlberg, S Jones, TP Miller, EJ Van Slyck, P Grozea, F Morrison, CA Coltman, RI Fisher. <u>ASTRO 2:191 (#142)</u> , 1991.	Lymphoma	06/01/78	12/01/87
*8796 (INT) (505)	A randomized phase III trial of MOPP/ABV Hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: Preliminary results of the intergroup trial. J Glick, A Tsiatis, R Schilsky, T Beck, M Oken, B Peterson, R Fisher. <u>ASCO 10:271 (#941)</u> , 1991.	Lymphoma	12/01/87	08/01/89
8819 (421)	Diffuse small cleaved cell lymphoma: A heterogeneous disease with distinct biologic subsets. C Leith, C Spier, T Grogan, G Gonzales, C Rangel, J Rybski, M Matzner, A Cantu, T Miller. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:77A (#450)</u> , 1991.	Lymphoma	02/15/89	Open
Multiple Studies (416)	Immunohistological quantification of cytolytic effector cells in B cell non-Hodgkin's lymphomas: A Southwest Oncology Group study. J Diaz, G Segal, R Tubbs, M Stoler, T Grogan. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:71A (#414)</u> , 1991.	Lymphoma		
Multiple Studies (418)	BCL-2/JH translocation in follicular lymphoid hyperplasia. R Braziel, T Grogan, M Berman, R Von Borstel, S Stanton, J Beckstead, P Suwanjindar, J Cossman. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:68A, (#398)</u> 1991.	Lymphoma		
Multiple Studies (419)	Refined working formulation (WF) categorization of lymphomas using phenotypic and genotypic analysis: A Southwest Oncology Group Central Repository study. T Grogan, C Spier, R Braziel, D Wirt, M Montiel, D Kerrigan, P Banks, C Kjeldsberg, B Nathwani, B Schnitzer, R Tubbs, N Levy, J Cossman, M Berman, R Fisher, T Miller. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:73A (#425)</u> , 1991.	Lymphoma		
Multiple Studies (420)	N-Cam positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement. WF Kern, CM Spier, TM Grogan. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:75A (#440)</u> , 1991.	Lymphoma		
None (423)	Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class I and class II antigen phenotype. JA Rybski, CM Spier, TP Miller, SL McGee, TM Grogan. <u>U.S. & Canadian Academy of Pathology Lab Invest 64:83A (#488)</u> , 1991.	Lymphoma		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
None (424)	Detection of Epstein-Barr virus (EBV) genome in Ki-1 (CD30) positive, large cell anaplastic lymphomas (LCAL) using the polymerase chain reaction (PCR). C Ross, J Schlegelmilch, T Grogan, B Schnitzer, C Hanson. <u>U.S. & Canadian Academy of Pathology Lab Invest</u> 64:88A (#487), 1991.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7808 (299)	Comparison of lymphangiography and CT scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease: A Southwest Oncology Group study. CM Mansfield, C Fabian, S Jones, EJ Van Slyck, P Grozea, F Morrison, TP Miller, C Seibert, K Ayyangar. <u>Cancer</u> 66(11):2295-2299, 1990.	Lymphoma	06/07/78	12/01/87
8323 (318)	Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. DD Von Hoff, S Dahlberg, RJ Hartsock, HJ Eyre. <u>JNCI</u> 82(16):1353-1355, 1990.	Lymphoma	05/21/84	05/15/88
8410 (324)	M-BACOD treatment for intermediate-and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial. BW Dana, S Dahlberg, TP Miller, RJ Hartsock, S Balcerzak, CA Coltman, Jr, JO Carden, K Hartley, RI Fisher. <u>JCO</u> 8(7):1155-1162, 1990.	Lymphoma	07/20/84	03/22/85
8503 (328)	Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A Groupwide Southwest Oncology Group study. TP Miller, S Dahlberg, JK Weick, JC Files, HJ Eyre, KB Pendergrass, RI Fisher. <u>JCO</u> 8(12):1951-1958, 1990.	Lymphoma	04/26/85	11/15/85
Multiple Studies (346)	Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. DJ Slymen, TP Miller, SM Lippman, CM Spier, DP Kerrigan, JA Rybski, CS Rangel, LC Richter, TM Grogan. <u>JCO</u> 8:986-993, 1990.	Lymphoma		
Multiple Studies	Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related disease course. SM Lippman, CM Spier, TP Miller, DJ Slyman, JA Rybski, TM Grogan. <u>Modern Pathology</u> 3:361-367, 1990.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

*8410/8503 8508 (358)	Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMACE-CytaBOM, and MACOP-B on Southwest Oncology Group studies. S Dahlberg, TP Miller, B Dana, J Weick, RI Fisher. <u>ASCO</u> 9:225 (#986), 1990.	Lymphoma		
8410/8503 8508	Treatment of intermediate and high grade non-Hodgkin's lymphoma with third generation chemotherapy regimens: Analysis of a Southwest Oncology Group phase II study. RI Fisher, S Dahlberg, TP Miller, B Dana, J Weick. <u>Lugano</u> , June 6-9, 1990.	Lymphoma	07/20/84	03/22/85

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8369	Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial. B Dana, S Dahlberg, B Schnitzer, CR Kjeldsberg, SE Jones, J Carden, R Mundis, B Trantum. <u>Invest New Drugs</u> 7:247-250, 1989.	Lymphoma	10/18/83	07/15/86
ABSTRACTS PUBLISHED/PRESENTED				
*781	Localized (stage I & II, A & B), Hodgkin's disease treated with extended field radiotherapy vs. involved field radiotherapy plus MOPP with 16 year followup: A Southwest Oncology Group study. CA Coltman, Jr, S Dahlberg, L Fuller, E Frei. <u>ASCO</u> 8:252 (#981), 1989.	Lymphoma	02/14/72	08/08/78
*7204/7426/ 7713	Long-term followup of patients with low grade lymphoma treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy or chemoimmunotherapy on Southwest Oncology Group studies. B Dana, S Dahlberg, T Miller, S Jones, E Chase, C Coltman, Jr, R Fisher. <u>ASCO</u> 8:257 (#1001), 1989.	Lymphoma		
*7204/7426/ 7713	Long-term survival of patients with nodular histiocytic (NH), diffuse poorly differentiated lymphocytic (DPDL), diffuse mixed (DM), and diffuse undifferentiated (DU) lymphoma treated with CHOP chemotherapy. RI Fisher, S Dahlberg, TP Miller, SE Jones, CA Coltman, Jr. <u>ASCO</u> 8:257 (#1003), 1989.	Lymphoma		
*7808	Efficacy of low dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in Hodgkin's disease, results of Southwest Oncology Group study 7808. C Fabian, S Dahlberg, T Miller, S Jones, P Grozea, F Morrison, C Mansfield. <u>ASCO</u> 8:253 (#987), 1989.	Lymphoma	06/01/86	12/01/87
8323	Evaluation of fludarabine phosphate (FLAMP) in patients with advanced mycosis fungoides (MF). A Southwest Oncology Group study. D Von Hoff, S Dahlberg, R Hartsock. <u>ASCO</u> 8:269 (#1050), 1989.	Lymphoma	05/21/84	05/15/88
*8410/8503/ 8508	The treatment of non-Hodgkin's lymphoma with m-BACOD, ProMACE-CytaBOM, and MACOP-B: The Southwest Oncology Group (SWOG) experience. J Weick, S Dahlberg, T Miller, B Dana, R Fisher. <u>ASCO</u> 8:254 (#990), 1989.	Lymphoma		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8907	High dose verapamil infusion added to chemotherapy reverses drug resistance in lymphoma patients in relapse. TP Miller, TM Grogan, CM Spier, SE Salmon, WS Dalton. <u>ASCO</u> 8:252 (#984), 1989.	Lymphoma	7/1/89	OPEN

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8503	Southwest Oncology Group clinical trials for intermediate-and high-grade non-Hodgkin's lymphomas. TP Miller, BW Dana, JK Weick, SE Jones, CA Coltman, Jr, S Dahlberg, RI Fisher. <u>Seminars in Hematology</u> 25(2), suppl 2, 17-22, 1988.	Lymphoma	4/26/85	11/15/85
Multiple Studies	Southwest Oncology Group studies in diffuse large cell lymphoma: A subset analysis. CA Coltman, Jr, S Dahlberg, SE Jones, TP Miller, BW Dana, JK Weick, EM McKelvey, RJ Hartsock, DO Dixon. Proceedings of the Third Nagoya International Symposium on Cancer Treatment, Nagoya, September 28-30, 1987. In: <u>Cancer Chemotherapy: Challenges for the Future</u> , Vol.3. K. Kimura et al (eds). Excerpta Medica, Tokyo, pp. 194-201, 1988.	Lymphoma		
Multiple Studies	Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. TM Grogan, SM Lippman, CM Spier, DJ Slyman, JA Rybski, CS Rangel, LC Richer, TP Miller. <u>Blood</u> 71:1157-1160, 1988.	Lymphoma		
Multiple Studies	HLA-DR immune phenotype predicts outcome for patients with diffuse large cell lymphoma. TP Miller, SM Lippman, CM Spier, DJ Slymen, TM Grogan. <u>JCO</u> 82:370-372, 1988.	Lymphoma		
Multiple Studies	The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B-cell diffuse large cell lymphoma. CM Spier, TM Grogan, SM Lippman, DJ Slymen, JA Rybski, TP Miller. <u>AM J Pathology</u> 113:118-126, 1988.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8410/8503/ 8508/8516	Southwest Oncology Group clinical trials for intermediate and high-grade non-Hodgkin's lymphomas. RI Fisher, TP Miller, BW Dana, SE Jones, S Dahlberg, CA Coltman, Jr. <u>Seminars in Hematology</u> 24(2):21-25, 1987.	Lymphoma		
Multiple Studies	Mitotic counts in follicular lymphomas. DJ Ellison, BN Nathwani, GE Metter, RR Turner, JS Burke, TP Miller, RB Mann, M Barcos, CR Kjeldsberg, CD Winberg, CC Whitcomb. <u>Human Pathology</u> 18:502-505, 1987.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
7204/7426/ 7713	Chop is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year Southwest Oncology Group follow up. CA Coltman, Jr, S Dahlberg, SE Jones, TP Miller, BW Dana, EM McKelvey, RH Hartsock, DO Dixon. <u>Third International Conference on Malignant Lymphoma</u> , Lugano, #65, 1987	Lymphoma		
7518	Chemotherapy alone versus combined modality therapy for stage III Hodgkin's disease: A five-year follow-up of a Southwest Oncology Group study. <u>Third International Conference on Malignant Lymphoma</u> , Lugano, June 10-13, 1987.	Lymphoma	08/07/78	04/14/80
8112	Alternated and syncopated CHOP-CVB. A test of the Goldie-Coldman hypothesis by the Southwest Oncology Group. L Dabich, MK Liepman, AF LoBuglio, BK Schnitzer, S Dahlberg, PN Grozea, JW Athens, RP Pugh. <u>ASCO</u> #C-810, 1987.	Lymphoma	9/10/82	12/23/82
8361	Toxicity and hematopoietic reserve following hemibody irradiation (HBI) and CHOP chemotherapy for non-Hodgkin's lymphoma (NHL). KM Sullivan, PE Neiman, S Dahlberg, R Rivkin, D Tesh. <u>ASCO</u> #C-770, 1987.	Lymphoma	01/03/84	03/20/86
8410	A phase II study of m-BACOD for intermediate and high grade malignant lymphomas (NHL). B Dana, S Jones, R Fisher, S Dahlberg, J Knost, S Balcerzak, C Ford, K Lanier, J Files, C Fabian, L White, J Carden, R Belt, CA Coltman, Jr. <u>ASCO</u> #C-777, 1987.	Lymphoma	07/20/84	03/22/85

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8410/ 8503/ 8508	Southwest Oncology Group clinical trials for intermediate and high grade non-Hodgkin's lymphomas. TP Miller, BW Dana, JK Weick, SE Jones, CA , Jr, S Dahlberg, RI Fisher. Presented at the <u>Third International Conference on Malignant Lymphoma</u> , Lugano, June 10-13, 1987.	Lymphoma		
8503	ProMACE-CytaBOM is active with acceptable toxicity in patients with unfavorable non-Hodgkin's lymphomas: A Groupwide Southwest Oncology Group study. TP Miller, S Dahlberg, SE Jones, RI Fisher, CA Coltman, Jr. <u>ASCO</u> #C-776, 1987.	Lymphoma	04/26/85	11/15/85
8508	MACOP-B chemotherapy for non-Hodgkin's lymphomas: A SWOG study. <u>ASH</u> #852, 1987.	Lymphoma	11/06/85	05/30/86
Multiple Studies	Toxicity (TOX) of interleukin-2 and lymphokine-activated killer (LAK) cell therapy. K Margolin, HS Jaffe, M Hawkins, MB Atkins, N Ciobanu, S Creekmore, CA Coltman, Jr. <u>ASCO</u> #C-988, 1987.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7426/7713	Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. DO Dixon, BA Neilan, SE Jones, DA Lipschitz, TP Miller, SE Salmon, PN Grozea, SP Balcerzak. <u>JCO</u> 4(3):296-305,1986.	Lymphoma		
7426/27/ 7713/14	What should be the morphologic criteria for the subdivision of follicular lymphomas? BN Nathwani, GE Metter, TP Miller, JS Burke, RB Mann, M Barcos, CR Kjeldsberg, DO Dixon, CD Winberg, CC Whitcomb, SE Jones. <u>Blood</u> 68(4):837-845, 1986.	Lymphoma	12/09/74	03/30/83
8116	A Phase II study of bisantrene in malignant lymphomas: A Southwest Oncology Group study. TP Miller, JD Cowan, BA Neilan, SE Jones. <u>Cancer Chemotherapy and Pharmacology</u> 16:67-69, 1986	Lymphoma	02/22/82	03/16/84
8264	Salvage treatment of poor-prognosis non-Hodgkin's lymphoma with cis-platinum, m-AMSA and MGBG: A Southwest Oncology Group study. BW Dana, SE Jones, CA Coltman Jr., WJ Stuckey. <u>Cancer Treat Rep</u> 70(2):291-292, 1986.	Lymphoma	08/11/82	03/16/84
ABSTRACTS PUBLISHED/PRESENTED				
7204/7426/ 7713	CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group followup. CA Coltman Jr., S Dahlberg, SE Jones, TP Miller, BW Dana, EM McKelvey, RJ Hartsock, DO Dixon. <u>ASCO</u> 5:197 (#774), 1986.	Lymphoma		
8245	Unfavorable histology lymphoma with alternating CHOP-CVB. A phase II Southwest Oncology Group study. L Dabich, PN Grozea, JW Athens, RM O'Bryan, SE Jones, FS Morrison, S Dahlberg, CA Coltman Jr. Presented for poster presentation at <u>ISH</u> , Sydney, Australia, May 11-16, 1986.	Lymphoma	12/23/82	03/16/84

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
*440/774/ 7406/7518 (232)	Bleomycin in combination with MOPP in the management of advanced Hodgkin's disease: A Southwest Oncology Group experience. CA Coltman Jr., SE Jones, PN Grozea, EJ DePersio, DO Dixon. Advances in Bleomycin Chemotherapy, San Francisco, California, September 14-15, 1984. In: <u>Bleomycin Chemotherapy</u> , BI Sikic, M Rozencweig, SK Carter, eds. Academic Press, Inc. Harcourt Brace Jovanovitch, New York. Chapter ii, pp. 137-153, 1985.	Lymphoma		
7518	Chemotherapy alone versus combined modality treatment for stage III Hodgkin's disease (H'sd): A five-year follow-up of Southwest Oncology Group (SWOG) study #7518. PN Grozea, EJ DePersio, CA Coltman Jr., CJ Fabian, FS Morrison, DO Dixon, SE Jones. <u>Proceedings of the Second International Conference on Malignant Lymphoma</u> , Lugano, June 13-16, 1984. F Cavilli, G Bonadonna, M Rozencweig, eds. Chap VI - Hodgkins Disease: Experimental and Therapeutic Approaches. Martinus Nijhoff Publishing, pp 343-341, 1985.	Lymphoma	10/30/75	04/14/80
7713/14	Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. SE Jones, PN Grozea, TP Miller, EJ Van Slyck, SP Balcerzak, JJ Costanzi, FS Morrison, HJ Eyre, CJ Fabian, L Dabich, DO Dixon, RJ Hartsack, TM Grogan, C Kjeldsberg, B Schnitzer. <u>JCO</u> 3(10):1318-1324, 1985.	Lymphoma	07/29/77	03/30/83
Multiple Studies	Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for lymphoma clinical studies. GE Metter, BN Nathwani, JS Burke, CD Winberg, RB Mann, M Barcos, CR Kjeldsberg, CC Whitcomb, DO Dixon, TP Miller, SE Jones. <u>JCO</u> 3(1):25-38, 1985.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
7433	Radiotherapy with and without chemotherapy in limited stage (I, IE, II, IIE) non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study. J Weick, J Hewlett, A Antunez, D Dixon. <u>ASCO</u> , #C-804, 1985.	Lymphoma	12/27/74	01/29/81
8461	Age and treatment outcomes in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group experience. BA Neilan, DO Dixon, SE Jones, DA Lipschitz, TP Miller. <u>ASCO</u> , #C-774, 1985.	Lymphoma	06/01/84	03/20/86

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7967	Vindesine, carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: A Southwest Oncology Group study. JK Weick, SE Jones, PN Grozea, CJ Fabian, DO Dixon. <u>Cancer Treat Rep</u> 68:963-967, 1984.	Lymphoma		
8005	Mitoxantrone in refractory NonHodgkin's lymphoma: A Southwest Oncology Group study. CA Coltman Jr, TM Coltman, SP Balcerzak, FS Morrison, DD Von Hoff. <u>Semin Oncol</u> 11(3 Suppl 1):50-53, 1984.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*7713/14	Chemotherapy with cyclophosphamide, Adriamycin, vincristine, and prednisone (CHOP) alone or with levamisole or levamisole plus BCG for non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study. S Jones, P Grozea, R O'Bryan, S Balcerzak, J Costanzi, J Athens, C Fabian, L Dabich, D Dixon. <u>ASCO</u> , #C-927, 1984.	Lymphoma		
7808	Response rates as a function of age in Hodgkin's disease: A SWOG study. C Fabian, R Sayre, D Dixon, C Mansfield. <u>ASCO</u> , #C-940, 1984.	Lymphoma		
*7808	Lack of correlation of Ann Arbor clinical parameters and biopsy determination of liver involvement in stage III and IV Hodgkin's disease: A Southwest Oncology Group (SWOG) study. C Fabian, A Denny, C Mansfield, D Dixon. <u>2nd International Conference on Malignant Lymphoma</u> (Lugano, June 13-16, 1984).	Lymphoma		
8005	Mitoxantrone in refractory non-Hodgkin's lymphoma. CA Coltman Jr, TM Coltman, SP Balcerzak, FS Morrison, DD Von Hoff. <u>2nd International Conference on Malignant Lymphoma</u> (Swiss League Against Cancer and Swiss Group for Clinical Cancer Research, Lugano, Switzerland, June 13-16, 1984), 98, 1984.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7406	Comparison of Adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group study. SE Jones, A Haut, JK Weick, HE Wilson, P Grozea, CJ Fabian, E McKelvey, GE Byrne Jr, R Hartsock, DO Dixon, CA Coltman Jr. <u>Cancer</u> 51:1339-1347, 1983.	Lymphoma		
7406/7518/ 781/760	Combined modality treatment of advanced Hodgkin's disease: Southwest Oncology Group studies. CA Coltman Jr, E Frei III, E Montague, PN Grozea, EJ DePersio, CJ Fabian, CM Mansfield, SE Jones, DO Dixon. In: <u>Management of Advanced Cancer</u> . P Periman, E Savlov, eds. Masson Publishing USA, 79-111, 1983.	Lymphoma		
7426/27	Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group study. SE Jones, PN Grozea, EN Metz, A Haut, RL Stephens, FS Morrison, R Talley, JJ Butler, GE Byrne, R Hartsock, D Dixon, SE Salmon. <u>Cancer</u> 51:1083-1090, 1983.	Lymphoma		
7761	The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation. JK Weick, A Antunez, TA Kraus, CJ Fabian, D Dixon. <u>Int J Rad Oncol Biol Phys</u> 9:1205-1207, 1983.	Lymphoma		
7860	Methyl-glyoxal bis guanyl hydrazone (Methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group. WA Knight III, C Fabian, JJ Costanzi, SE Jones, CA Coltman Jr. <u>Investigational New Drugs</u> 1:235-237, 1983.	Lymphoma		
7912	Gallium Nitrate in malignant lymphoma: A Southwest Oncology Group study. JK Weick, RL Stephens, LH Baker, SE Jones. <u>Cancer Treat Rep</u> 67:823-825, 1983.	Lymphoma		
7918	Phase II study of Amsacrine (m-AMSA) in advanced lymphomas: A Southwest Oncology Group study. JK Weick, SE Jones, DH Ryan. <u>Cancer Treat Rep</u> 67:489-492, 1983.	Lymphoma		
7961	Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease (HD): A Southwest Oncology Group Phase II study. TP Miller, SE Jones, JM Rainey. <u>Cancer Treat Rep</u> 67:739-740, 1983.	Lymphoma		

7963	Phase II evaluation of Amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. FR Ahmann, F Meyskens Jr, SE Jones, RM Bukowski, JH Saiers, DH Ryan, J Costanzi, CB Vaughn, CA Coltman Jr. <u>Cancer Treat Rep</u> 67:697-700, 1983.	Melanoma, Myeloma, Lymphoma, Lung, Breast
8005	Mitoxantrone hydrochloride (NSC-301739) in lymphoma. A Southwest Oncology Group study. CA Coltman Jr, TM McDaniel, SP Balcerzak, FS Morrison, DD Von Hoff. <u>Investigational New Drugs</u> 1:065-070, 1983.	Lymphoma
*8005	Mitoxantrone hydrochloride in lymphoma. CA Coltman Jr, TM McDaniel, SP Balcerzak, FS Morrison, DD Von Hoff. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Mitoxantrone</u> 212:52-55, 1983.	Lymphoma
8005	Mitoxantrone hydrochloride in lymphoma. CA Coltman Jr, TM McDaniel, SP Balcerzak, FS Morrison, DD Von Hoff. <u>Cancer Treat Rev</u> 10(Suppl B):73-76, 1983.	Lymphoma
*8005/8032	Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies. CA Coltman Jr, JH Saiki, FJ Panettiere, SP Balcerzak, RL Stephens, FS Morrison, DO Dixon, DD Von Hoff. In: <u>3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy</u> (Brussels, October 15-17, 1981). M Rozenzweig, DD Von Hoff, MJ Staquet, eds. <u>New Anticancer Drugs: Mitoxantrone and Bisantrone</u> . New York: Raven Press, 115-124, 1983.	Leukemia, Lymphoma
*8108/16/ 17/18/19/ 20/61/ 8214	Southwest Oncology Group studies with Bisantrone. CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller, E Surwit, DS Alberts, RA Shildt, F Panettiere, GM Mills, PB Wasserman, TM McDaniel. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Bisantrone</u> 213:1-4, 1983.	Myeloma, Lymphoma, GYN, GI, Melanoma, Leukemia, Sarcoma

ABSTRACTS PUBLISHED/PRESENTED

*7713	Prevention of central nervous system relapse in unfavorable histology non-Hodgkin's lymphoma. A Southwest Oncology Group study. KL Fielder, SE Jones, DO Dixon, PN Grozea, RM O'Bryan, JJ Costanzi, SP Balcerzak. <u>American Society of Hematology</u> , poster presentation, December 1983.	Lymphoma
7713/14	Prevention of CNS relapse in unfavorable histology non-Hodgkin's lymphoma. KL Fielder, SE Jones, DO Dixon, PN Grozea, RM O'Bryan, JJ Costanzi, SP Balcerzak. <u>Blood</u> 62 (Suppl 1):212a (753), 1983.	Lymphoma
7808	Correlation of clinical and biopsy determination of liver involvement in Stage III and IV Hodgkin's disease: A Southwest Oncology Group (SWOG) study. C Fabian, G Bascom, C Mansfield. <u>ASCO</u> , #C-843, 1983.	Lymphoma
7967	Vindesine, BCNU, Adriamycin and Prednisone (EBAP) in malignant lymphoma. For the Southwest Oncology Group (SWOG). JK Weick, SE Jones. <u>ASCO</u> , #C-818, 1983.	Lymphoma

* Abstracts presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
160/781/ 774/775	Second malignancies complicating Hodgkin's disease - Ten year followup: A Southwest Oncology Group study. CA Coltman Jr, DO Dixon. <u>Cancer Treat Rep</u> 66:1023-1033, 1982.	Lymphoma		
160/781/ 7518	Conclusions from clinical trials of the Southwest Oncology Group. SE Jones, CA Coltman Jr, PN Grozea, EJ DePersio, DO Dixon. <u>Cancer Treat Rep</u> 66:847-854, 1982.	Lymphoma		
160/781/ 7518	The role of combined radiotherapy and chemotherapy in the primary management of Hodgkin's disease. CA Coltman Jr, JW Myers, E Montague, LA Fuller, PN Grozea, EJ DePersio, DO Dixon. In: <u>Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment</u> . Academic Press, 523-536, 1982.	Lymphoma		
7204/05/ 7426	The clinical significance of the morphologic subdivision of diffuse, "Histiocytic" Lymphoma: A study of 162 patients treated by the Southwest Oncology Group. BN Nathwani, DO Dixon, SE Jones, RT Hartsock, JW Rebuck, GE Byrne Jr, WW Sheehan, H Kim, CA Coltman Jr, H Rappaport. <u>Blood</u> 60:1068-1074, 1982.	Lymphoma		
7406	Mistaken clinical and pathologic diagnosis of Hodgkin's Disease: A Southwest Oncology Group study. TP Miller, GE Byrne, SE Jones. <u>Cancer Treat Rep</u> 66:645-651, 1982.	Lymphoma		
7406	Surgical restaging of Hodgkin's disease. GE Goodman, SE Jones, HV Villar, ME Silverstien, L Dabich, SR Newcome, and the Southwest Oncology Group. <u>Cancer Treat Rep</u> 66: 751-757, 1982.	Lymphoma		
7426	Chemoimmunotherapy of malignant lymphoma. SE Jones. In: <u>Of Human Cancer</u> . W Terry, S Rosenberg, eds. New York: Elsevier-North Holland, 55-60, 1982.	Lymphoma		
7518	A Southwest Oncology Group study: Chemotherapy versus chemotherapy plus radiotherapy in the treatment of Stage III Hodgkin's disease. PN Grozea, EJ DePersio, CA Coltman Jr, CJ Fabian, FS Morrison, EA Gehan, SE Jones. In: <u>Recent Results in Cancer Research: Adjuvant Therapies of Cancer</u> . G Matte, G Bonadonna, S Salmon, eds. New York: Springer-Verlag, 83-91, 1982.	Lymphoma		
7821	Phase II evaluation of Maytansine in refractory non-Hodgkin's lymphoma. A Southwest Oncology Group study. V Ratanatharathorn, N Gad-el-Mawla, HE Wilson, JD Bonnet, SE Rivkin, R Mass. <u>Cancer Treat Rep</u> 66:1587-1588, 1982.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

*160/781/ 774/775	Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group Ten Year Follow-up. CA Coltman Jr, DO Dixon. <u>ASCO</u> , #C-644, 1982.	Lymphoma
*7518	Chemotherapy alone vs. chemotherapy plus radiotherapy for stage III Hodgkin's disease. A Southwest Oncology Group study. PN Grozea, EJ DePersio, DO Dixon, CA Coltman Jr, SE Jones. <u>International Society of Hematology</u> , 1982.	Lymphoma
7518	Chemotherapy versus chemotherapy plus radiotherapy in treatment of Stage III Hodgkin's disease. A Southwest Oncology Group study. PN Grozea, EJ DePersio, CA Coltman, CJ Fabian, FS Morrison, EA Gehan, SE Jones. <u>Cancerogram</u> , May 1982.	Lymphoma
7808	Chemotherapy and involved field radiotherapy for Stage III-IV Hodgkin's disease. C Mansfield. <u>Radiologic Soc of North Am</u> , 1982.	Lymphoma
7860	Methyl-glyoxal Bis-Guanylhydrazone (Methyl-GAG) in the management of Non-Hodgkin's lymphoma (NHL). JG Kuhn, WA Knight III, TM McDaniel, CA Coltman Jr, JP Whitecar, C Fabian, JJ Costanzi. <u>ASCO</u> , #C-635, 1982.	Lymphoma

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

772/73 774/75	Management of Stage III and Stage IV Hodgkin's Disease. CA Coltman Jr. In: <u>Principles of Cancer Treatment</u> . New York: McGraw-Hill, 808-818, 1981.	Lymphoma		
7204/7426	Lymphoblastic lymphoma: A clinicopathologic study of 95 patients. BN Nathwani, LW Diamond, CD Winberg, H Kim, RM Bearman, JH Glick, SE Jones, RA Gams, NI Nissen, H Rappaport. <u>Cancer</u> 48:2347-2357, 1981.	Lymphoma		
7204/7426/ 7707/7713	The chemotherapy of lymphoblastic lymphoma. JB Voakes, SE Jones, EM McKelvey. <u>Blood</u> 57:186-188, 1981.	Lymphoma		
7707	Treatment of recurrent lymphomas with BCNU, Doxorubicin, and Prednisone (VBAP): A Southwest Oncology Group study. JK Weick, SE Jones, A Haut, R Fisher, DO Dixon. <u>Cancer Treat Rep</u> 65:611-614, 1981.	Lymphoma		
7707/7967	Vincristine or Vindesine plus BCNU, Adriamycin and Prednisone for refractory lymphoma. SE Jones, TP Miller, A Robertone, JK Weick. In: <u>Proceedings of the International Vinca Alkaloid Symposium - Vindesine</u> . S. Karger, 1981.	Lymphoma		
7808	A protocol for combined modality treatment for Stage III and IV Hodgkin's disease: A Southwest Oncology Group study. CJ Fabian, NI Abdou, C Mansfield, A LoBuglio. In: <u>Immunopharmacologic Effects of Radiation Therapy</u> , 487-498, 1981.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

?	MGBG in malignant lymphoma, a Phase II study. WA Knight III. <u>Minutes of the Phase I-II Working Group, National Cancer Institute</u> , 211-212, June 1981.	Lymphoma		
7760	Results of a pilot study using COP-BLEO plus low-dose involved field radiotherapy. C Fabian, CM Mansfield. <u>ARS</u> , #43, 1981.	Lymphoma		
7761	The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with combination chemotherapy and total body irradiation. JK Weick, AR Antunez, CJ Fabian. <u>Int J Radiat Oncol Biol Phys</u> 7(9):1289, 1984.	Lymphoma		
*8005/32	Mitoxantrone Hydrochloride (NSC-30179) in hematologic malignancies. CA Coltman Jr, JH Saiki, FJ Panettiere, SP Balcerzak, RL Stephens, FS Morrison, DO Dixon, DD Von Hoff. <u>3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy</u> (Brussels, 1981).	Lymphoma		

* Abstracts presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Multiple primary cancers in Hodgkin's disease. RS Brocy, D Schottenfield. <u>Semin Oncol</u> 7(2):187-201, 1980.	Lymphoma		
772/73 774/75	Chemotherapy of advanced Hodgkin's Disease. CA Coltman Jr. <u>Seminars in Oncology</u> 7:155-173, 1980.	Lymphoma		
None	Lymphoma. CA Coltman Jr, RA Gams, JH Glick, RD Jenkins. In: <u>Cancer Research: Impact of the Cooperative Groups</u> . B Hoogstraten, ed. Masson Publishing, USA, 39-84, 1980.	Lymphoma		
Several Studies	Human lymphomas. SE Jones. In: <u>Clinical Immunotherapy</u> . AF LoBuglio, ed. New York, Marcel Dekker, Immunology Series, Vol. II, 1980.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
7406	Improved remission induction chemotherapy for patients with advanced Hodgkin's disease: A Southwest Oncology Group study. SE Jones, RJ Fisher, J Jones, CA Coltman Jr. <u>ASCO</u> , #C-571, 1980.	Lymphoma		
7426/27	Chemoimmunotherapy of Non-Hodgkin's lymphoma. SE Jones, SE Salmon, C Haskins. <u>Immunotherapy of Cancer: Present Status of Trials in Man</u> , p. 28, April, 1980.	Lymphoma		
7518	MOPP plus Bleomycin versus MOPP plus Bleomycin plus total nodal irradiation for Stage III Hodgkin's Disease. PN Grozea, EJ DePersio, RJ Fisher, CA Coltman Jr, SE Jones. <u>Joint Meeting of the 18th Congress of the International Society of Hematology and 16th Congress of the International Society of Blood Transfusion</u> , #1223, 1980.	Lymphoma		
7963	A broad Phase II trial of AMSA with <u>in vitro</u> stem cell culture drug sensitivity correlation. F Ahmann, F Meyskens, S Jones, B Durie, D Alberts, S Salmon. <u>ASCO</u> , #C-199, 1980.	Breast, Lung, Lymphoma, Melanoma, Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
781	Extended field radiotherapy vs. involved field radiotherapy + MOPP in Stage I & II Hodgkin's disease. CA Coltman, L Fuller, R Fisher, E Frei III. In: <u>Adjuvant Therapy of Cancer II</u> , Salmon and Jones, eds., Grune and Stratton, Inc., pp. 129-136, 1979.	Lymphoma		
7204/05	Combination chemotherapy for mycosis fungoides. P Grozea, S Jones, E McKelvey, CA Coltman, R Fisher, C Haskins. <u>Cancer Treat Rep</u> 63(4):647-653, 1979.	Lymphoma		
7413	Phase II evaluation of cis-dichlorodiammineplatinum (II) in lymphoma. A Southwest Oncology Group study. AH Rossof, CA Coltman, Jr, SE Jones, RW Talley. <u>Cancer Treat Rep</u> 63(9-10):1605-1608, 1979.	Lymphoma		
7426/27	Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group study. SE Jones, PN Grozea, EN Metz, A Haut, RL Stephens, FS Morrison, JS Butler, GE Byrne, Jr, TE Moon, R Fisher, CL Haskins, CA Coltman, Jr. <u>Cancer</u> 43(2):417-425, 1979.	Lymphoma		
7426/27	Involvement of the central nervous system by non-Hodgkin's lymphoma. The Southwest Oncology Group experience. T Herman, N Hammond, S Jones, J Butler, G Byrne, E McKelvey. <u>Cancer</u> 43(1):390-397, 1979.	Lymphoma		
7426/27	Adjuvant immunotherapy with BCG in non-Hodgkin's lymphoma. S Jones, S Salmon, R Fisher. In: <u>Adjuvant Therapy of Cancer II</u> , pp. 163-171, 1979.	Lymphoma		
7580	Neoantigen response in patients successfully treated for lymphoma. A Southwest Oncology Group study. GW King, PN Grozea, HJ Eyre, AF LoBuglio. <u>Annals of Intern Med</u> 90(6):892-895, 1979.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

?	Chemoimmunotherapy of non-Hodgkin's lymphoma. SE Jones. <u>Medical Oncology: Abstracts of the 5th Annual Meeting of the Medical Oncology Society</u> held in Nice, France, December 1-3, 1979. Medical Oncology Society, Nice, France. 52, 1979.	Lymphoma
?	Death while in complete remission (CR) among patients with advanced Hodgkin's disease treated with intermittent combination chemotherapy. CJ Trauth. <u>Proc AACR</u> 20:397, 1979.	Lymphoma
774/5	MOPP + low dose bleomycin (MOPP + LDB) for advanced Hodgkin's disease. CA Coltman, Jr, et al. 1979.	Lymphoma
*781	Patterns of relapse in localized (Stage I & II Hodgkin's Disease (HD) following extended field radiotherapy (EFXRT) vs. involved field radiotherapy (IFXRT) plus MOPP. C Coltman, L Fuller, R Fisher, E Frei. <u>International Conference on the Adjuvant Therapy of Cancer</u> #13, 1979.	Lymphoma
7205	Clinical features of malignant lymphomas. E McKelvey, R Fisher, C Haskins. <u>ASCO</u> , #C-380, 1979.	Lymphoma
7426	Improved survival in nodular lymphomas with chemoimmunotherapy. S Jones, S Salmon, R Fisher, C Haskins, G Byrne, J Butler. <u>ASCO</u> , #C-89, 1979.	Lymphoma
7426	Improved survival in nodular lymphomas with chemoimmunotherapy. S Jones, S Salmon, R Fisher, C Haskins, G Byrne, J Butler. <u>Proc AACR</u> 20:313, 1979.	Lymphoma
7426/27	Adjuvant use of BCG in the non-Hodgkin's lymphomas. S Jones, S Salmon. <u>International Conference on the Adjuvant Therapy of Cancer</u> #17, 1979.	Lymphoma
518	Chemotherapy vs. chemotherapy + radiotherapy for Stage III Hodgkin's disease. P Grozea, E DePersio, R Fisher, C Coltman, S Jones. <u>AACR</u> , #481, 1979.	Lymphoma
*7518	Chemotherapy versus chemotherapy plus radiotherapy for Stage IIIA, IIIB Hodgkin's disease. A Southwest Oncology Group (SWOG) study. EJ DePersio, PN Grozea, R Fisher, SE Jones, CA Coltman, Jr. <u>Proceedings of American Society of Therapeutic Radiologists</u> , #110, 1979.	Lymphoma
7707	Treatment of refractory lymphoma with vincristine, BCNU, Adriamycin, and Prednisone (VBAP). J Weick, S Jones. <u>ASCO</u> , #C-266, 1979.	Lymphoma
7707	Treatment of refractory lymphoma with vincristine, BCNU, Adriamycin, and Prednisone (VBAP). J Weick, S Jones. <u>Proc AACR</u> 20:346, 1979.	Lymphoma
7761	Primary therapy of Stage III & IV diffuse Non-Hodgkin's Lymphoma with combination chemotherapy, total body irradiation. J Weick, A Antunez, C Fabian. <u>AACR</u> 20:145 (#583), 1979.	Lymphoma

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Second malignancies complicating Hodgkin's disease: The Southwest Oncology Group experience. DM Toland, CA Coltman, Jr, TE Moon. <u>Cancer Clinical Trials</u> 1(1):27-33, 1978.	Lymphoma		
774/775/ 7406	Bleomycin in combination with MOPP for the management of Hodgkin's disease: Southwest Oncology Group experience. CA Coltman, Jr, SE Jones, PN Grozea, E DePersio, TE Moon. In: <u>Bleomycin - Current Status and New Developments</u> , Carter SK, Crooke ST, Umezawa H, eds., New York: Academic Press, Inc., pp. 227-242, 1978.	Lymphoma		
781	Second malignancies complicating Hodgkin's disease: The Southwest Oncology Group experience. CM Toland, CA Coltman, Jr, TE Moon. <u>Cancer Clin Trials</u> 1:27-33, 1978.	Lymphoma		
7407	Evaluation of VP-16-213 in malignant lymphoma and melanoma. JW Cecil, JW Quagliana, CA Coltman, Jr, M Al-Sarraf, T Thigpen, CW Groppe, Jr. <u>Cancer Treat Rep</u> 62(5):801-803, 1978.	Lymphoma		
7426/27	Systematic restaging in non-Hodgkin's lymphoma: the need to define complete remission. TS Herman, SE Jones. <u>Recent Results in Cancer Res</u> 65:73-80, 1978.	Lymphoma		
7426/27	Systematic restaging in patients with Hodgkin's disease: a Southwest Oncology Group study. TS Herman, SE Jones. <u>Cancer</u> 42(4):1976-1978, 1978.	Lymphoma		
7622	Mycosis Fungoides: Current Status. SE Jones et al. 1978.	Lymphoma		
7713/14	Chemoimmunotherapy versus chemotherapy for remission induction in patients with non-Hodgkin's lymphoma: Progress report of a Southwest Oncology Group study. SE Jones. <u>Recent Results Cancer Res</u> 65:164-169, 1978.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

?	Medical management of non-Hodgkin's lymphoma. GP Bodey, <u>Third International Symposium on Oncology Held by Taj Pahlavi Cancer Institute in Tehran, 4-8 March 1978.</u> Taj Pahlavi Cancer Institute, Pahlavi Medical School, Tehran University, Tehran, Iran:115, 1978.	Lymphoma
?	Combination chemotherapy for the treatment of advanced stages of mycosis fungoides. PN Grozea, SE Jones, EM McKelvey. <u>AACR</u> 19:66, 1978.	Lymphoma
774/775	MOPP plus low dose bleomycin (MOPP+LDB) for advanced Hodgkin's disease (HD)--A five year followup. CA Coltman, Jr, SE Jones. <u>AACR</u> 19:329, 1978.	Lymphoma
774/775	Death while in remission (CR) among patients with advanced Hodgkin's disease treated with intermittent combination chemotherapy. CJ Trauth, CA Coltman, Jr. <u>Blood</u> 52:268 (#611), 1978.	Lymphoma
7204/05	Clinical features of malignant lymphoma. McKelvey et al. 1978.	Lymphoma
7204/05	Review of CHOP-HOP combined chemotherapy in malignant lymphoma. McKelvey et al. <u>AACR</u> 19: 415, 1978.	Lymphoma
7406	Comparison of 3 combination drug programs for advanced Hodgkin's disease (HD): A preliminary report of the Southwest Oncology Group (SWOG) MOPP #5 study. SE Jones, CA Coltman, Jr. <u>AACR</u> 19:333, 1978.	Lymphoma
7580	Neoantigen response in successfully treated lymphoma patients. G King, P Grozea, A LoBuglio. <u>AACR</u> (#364), 1978.	Lymphoma

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Chemotherapy of non-Hodgkin's lymphomas. CG Schmidt. <u>Strahlentherapie</u> 153(5):283-292, 1977.	Lymphoma		
160	Chemotherapy and total nodal radiotherapy in pathological stage IIB, IIIA and IIIB Hodgkin's disease. CA Coltman Jr, E Montague, TE Moon. In: <u>Adjuvant Therapy of Cancer</u> , SE Salmon, SE Jones, eds., North Holland, Amsterdam: Elsevier, pp. 529-536, 1977.	Lymphoma		
765/6	Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group studies. CA Coltman Jr, JK Luce, McKelvey EM, SE Jones, TE Moon. <u>Cancer Treat Rep</u> 61(5):1067-1078, 1977.	Lymphoma		
772/3	Splenectomy, chemotherapy, and survival in Hodgkin's disease. FJ Panettiere, CA Coltman, Jr, and FC Delaney. <u>Arch Int Med</u> 137:341-343, 1977.	Lymphoma		
7204/05	Curability of non-Hodgkin's lymphomas. EM McKelvey and TE Moon. <u>Cancer Treat Rep</u> 61:1185-1190, 1977.	Lymphoma		
7426/27	Systematic re-staging in the management of non-Hodgkin's lymphomas. TS Herman and SE Jones. <u>Cancer Treat Rep</u> 61:1009-1015, 1977.	Lymphoma		
7426/27	Adjuvant immunotherapy with BCG in lymphoma. SE Jones and SE Salmon. In: <u>Adjuvant Therapy of Cancer</u> . Salmon SE, Jones SE (eds.), Elsevier/ North Holland Press, Amsterdam, pp. 549-556, 1977.	Lymphoma		
7426/27	Chemoimmunotherapy of non-Hodgkin's lymphoma with BCG: A preliminary report. SE Jones, SE Salmon, TE Moon, JJ Butler. In: <u>Immunotherapy of Cancer: Present Status of Trials in Man</u> . Terry, W.D., Windhorst, D. (eds), Raven Press, New York, pp. 519-528, 1977.	Lymphoma		
7435	Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study. SE Jones, WG Tucker, A Haut, BL Tranum, C Vaughn, EM Chase and BGM Durie. <u>Cancer Treat Rep</u> 61:1617-1621, 1977.	Lymphoma		
Multiple Studies	Histopathologic review of lymphoma cases from the Southwest Oncology Group. SE Jones, JJ Butler, GE Bryne, CA Coltman, Jr, TE Moore. <u>Cancer</u> 39(3):1071-1076, 1977.	Lymphoma		

ABSTRACTS PUBLISHED/PRESENTED

160	Chemotherapy (MOPP) and total nodal radiotherapy (TNRT) in pathological stage II B, III A and B Hodgkin's disease. CA Coltman, Jr. <u>AACR</u> , #861, 1977.	Lymphoma
160	Chemotherapy (MOPP) and total nodal radiotherapy (TNRT) in pathological stage II B, III A and B Hodgkin's disease (HD). CA Coltman, Jr, E Montague, C Haskins and TE Moon. <u>International Conference on Adjuvant Therapy of Cancer</u> , 1977.	Lymphoma
*781	Second malignancies (SM) complicating Hodgkin's disease: the Southwest Oncology Group experience. DM Toland and CA Coltman, Jr. <u>ASCO</u> 18:351 (#C-340), 1977.	Lymphoma
*781	Patterns of relapse in localized (Stage I & II) Hodgkin's disease (HD) following extended field radiotherapy (EFXRT) vs. involved field radiotherapy (IFXRT) plus MOPP. CA Coltman Jr, LM Fuller. <u>Blood</u> 50:188 (#340), 1977.	Lymphoma
7204/05	Central nervous system (CNS) lymphoma: clinico-pathologic features and reduced incidence with parenteral cytosine arabinoside. SE Jones, N Hammond, E McKelvey, TS Herman, GE Byrne and JJ Butler. <u>Blood</u> 50:194, #359, 1977.	Lymphoma
7426/27	Systematic restaging in Hodgkin's disease. TS Herman and SE Jones. <u>AACR</u> , #386, 1977.	Lymphoma
7426/27	Chemoimmunotherapy of non-Hodgkin's lymphoma (NHL). SE Jones, SE Salmon, TE Moon and JJ Butler. <u>ASCO</u> , #C-100, 1977.	Lymphoma

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
440	Phase II evaluation of bleomycin. CD Haas, CA Coltman Jr, JA Gottlieb, A Haut, JK Luce, RW Talley, B Samal, HE Wilson, B Hoogstraten. <u>Cancer</u> 38(7):8-12, 1976.	Lymphoma		
7204/05	Hydrosyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. EM McKelvey, JA Gottlieb, HE Wilson, A Haut, RW Talley, R Stephens, M Lane, JF Gamble, SE Jones, PN Grozea, J Gutterman, CA Coltman Jr, TE Moon. <u>Cancer</u> 38(4):1484-1493, 1976.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*758/9	MOPP maintenance (MM) vs. unmaintained re-remission (UMR) for MOPP induced complete remission (CR) of advanced Hodgkin's disease (HD). CA Coltman, Jr, E Frei III and TE Moon. <u>ASCO</u> , #C-211, 1976.	Lymphoma		
*7204/5	Cyclophosphamide vs. arabinosyl cytosine combination maintenance chemotherapy in malignant lymphoma. EM McKelvey. <u>ASCO</u> , #C-99, 1976.	Lymphoma		
*7406/7426	Lymphoma pathology repository review in the Southwest Oncology Group (SWOG). SE Jones, JJ Butler, GE Byrne Jr, CA Coltman Jr. <u>ASCO</u> 17:249 (#C-49), 1976.	Lymphoma		
*7435	Phase II trial of piperazinedione (crystalline antibiotic) in lymphoma and multiple myeloma. S Jones, S Salmon and members of the Southwest Oncology Group. <u>AACR</u> , #179, 1976.	Lymphoma Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1975**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7200	Methyl CCNU in treatment of solid tumors and lymphomas. BL Trantum, JA Gottlieb, A Haut, S Rivkin and E Weber. <u>Cancer</u> 35:1148-1153, 1975.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
*753/5/6	High rate and long duration of complete remission in malignant lymphoma treated with combined oral cyclo- phosphamide and prednisone and intravenous vincristine. JK Luce, EA Gehan, JF Gamble, HE Wilson, RW Monto and RW Talley. <u>AACR</u> , #514, 1975.	Lymphoma		
*772	Splenectomy and survival in Hodgkin's disease. FJ Panettiere, CA Coltman, Jr and FC Delaney. <u>ASCO</u> , #1089, 1975.	Lymphoma		
*7204/5	Hydroxyldaunomycin (adriamycin) combination chemo- therapy in non-Hodgkin's lymphoma. EM McKelvey, JA Gottlieb, A Haut and M Lane. <u>ASCO</u> , #1050, 1975.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1974**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
7200	Methyl CCNU in Hodgkin's disease and other tumors. BL Trantum, A Haut, S Rivkin and E Weber. <u>ASCO</u> , 1974.	Lymphoma		
7204/5	Hydroxyldaunomycin (adriamycin) combination chemotherapy for advanced non-Hodgkin's lymphoma. EM McKelvey, JU Gutterman and CA Coltman, Jr. <u>ASH</u> , 1974.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
3756/9	Chemotherapy of Hodgkin's disease. JK Luce, E Frei III, EA Gehan, CA Coltman, Jr, RW Talley, RW Monto. <u>Arch Intern Med</u> 131:391-395, 1973.	Lymphoma		
772/3	Splenectomy effects on chemotherapy in Hodgkin's disease. F Panettiere, CA Coltman, Jr. <u>Arch Intern Med</u> 131:362-366, 1973.	Lymphoma		
ABSTRACTS PUBLISHED/PRESENTED				
443/446	CCNU (1-2-chloroethyl-3-cyclohexyl-1-nitrosourea) and bleomycin in the treatment of solid tumors and lymphoma. B Hoogstraten, JK Luce. <u>AACR</u> , 1973.	Lymphoma		
6774/775	Five drug combination chemotherapy for advanced Hodgkin's disease (HD). CA Coltman, Jr., FC Delaney. Presented to the Central Society for Clinical Research in Chicago, IL. <u>Clinical Research</u> 21:876, 1973.	Lymphoma		
780	Remission induction chemotherapy of disseminated malignant lymphoma with combination bleomycin, cyclophosphamide, vincristine and prednisone. JK Luce, FC Delaney, EA Gehan. <u>AACR</u> , 1973.	Lymphoma		
7200	Methyl CCNU in Hodgkin's disease and other tumors. BL Trantum, A Haut, S Rivkin and E Weber. <u>ASCO</u> , 1973.	Lymphoma		
7204/5	Hydroxyldaunomycin (adriamycin) combination chemotherapy for advanced non-Hodgkin's lymphoma. EM McKelvey, JU Gutterman, CA Coltman, Jr. <u>ASH</u> , 1973.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
310	Evaluation of uracil mustard in children with Hodgkin's disease, lymphosarcoma, and soft tissue sarcoma. DH Berry, WW Sutow, TJ Vietti, DJ Fernbach, MP Sullivan, ME Haggard and DM Lane. <u>J Clin Pharmacol New Drugs</u> 12(4):169-173, 1972.	Lymphoma Sarcoma		
428	Dimethyl traizeno inidazole carboxamide (DIC) (NSC-45388) in the treatment of lymphoma. E Frei III, JK Luce, RW Talley, VK Vaitkevicius and HE Wilson. <u>Cancer Chemotherapy Reports</u> 56(5):1972.	Lymphoma		
7204/5	Chemotherapy of malignant lymphoma with adriamycin. JA Gottlieb, JU Gutterman, KB McCredie and E Frei III. <u>14th International Congress of Hematology</u> , Sao Paulo, Brazil, #581:1972.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1971**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

753/755 760/2	Combined cyclophosphamide, vincristine and prednisone therapy of malignant lymphoma. JK Luce, JF Gamble, HE Wilson, RW Monto, BL Isaacs, RL Palmer, CA Coltman, Jr, JS Hewlett, EA Gehan and E Frei III. <u>Cancer</u> 28(2):306-317, 1971.	Lymphoma		
------------------	---	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Management of patients with lymphoma. Clinico-pathological panel discussion. JJ Butler, LM Fuller, JF Gamble, JK Luce, CC Shullenberger, S Wallace. (<u>A Collection of Papers Presented at the Fourteenth Annual Clinical Conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute, Houston, TX) Year Book Medical Publishers, Chicago, IL:375-386, 1970.	Lymphoma		
?	Perspectives in leukemia-lymphoma research. E Frei III. In: <u>Leukemia-Lymphoma (Collection of Papers Presented at the Fourteenth Annual Clinical conference on Cancer</u> , 1969, at the M.D. Anderson Hospital) Chicago, IL, Year Book Medical Publishers:365-373, 1970.	Leukemia Lymphoma		
?	Supportive therapeutic measures for patients under treatment for leukemia-lymphoma. EJ Freireich, GP Bodey, DS de Jongh, JE Curtis, EM Hersh. In: <u>Leukemia-Lymphoma (A collection of papers presented at the Fourteenth Annual Clinical Conference on Cancer</u> , 1969, at the M.D. Anderson Hospital and Tumor Institute, Houston, TX). Year Book Medical Publishers, Chicago, IL:275-284, 1970.	Leukemia Lymphoma		
?	Hodgkin's disease. JS Hart, E Frei III. <u>Current Therapy</u> . Philadelphia, PA., W.B. Saunders Co.:235-239, 1970.	Lymphoma		
?	Host defense mechanisms in lymphoma and leukemia. EM Hersh, JE Curtis, JE Harris, C McBride, R Alexanian, R Rossen. In: <u>Leukemia-Lymphoma. 14th Annual Clinical Conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute, Houston, TX. Year Book Medical Publishers, Inc.:149-167, 1970.	Leukemia Lymphoma		
?	Chemotherapy for lymphoma. Current status. JK Luce. In: <u>Leukemia-Lymphoma, A collection of papers presented at the Fourteenth Annual Clinical conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute, Houston, TX. Year Book Medical Publishers, Chicago, IL: 265-304, 1970.	Leukemia Lymphoma		
?	Monoclonal macroglobulinemia in malignant lymphoma. DF Moore, PJ Migliore, CC Shullenberger, R Alexanian. <u>Ann of Internal Medicine</u> 72:43-47, 1970.	Lymphoma		
?	Monclonal macroglobulinemia in malignant lymphoma. DF Moore, FJ Migliore, JJ Butler, CC Shullenberger, R Alexanian. <u>Xth International Cancer Congress</u> , Houston, TX, Abstract No. 528:327, 1970,	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1967**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Cyclophosphamide (NSC-26271) therapy for children with generalized lymphoma and Hodgkin's disease. MP Sullivan. <u>Cancer Chemotherapy Reports</u> 51:393-396, 1967.	Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Phase II studies of hydroxyurea (NSC-32065) in adults: Multiple myeloma and lymphoma. P Davis. <u>Cancer</u> <u>Chemotherapy Reports</u> 40:51-52, 1964.	Myeloma Lymphoma		